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Abstract 
Current prognostic techniques for Cutaneous Malignant Melanoma (CMM), a 
highly aggressive and drug resistant skin cancer, are inadequate at managing 
the disease and identifying early stage patients requiring treatment. It is 
thought that Circulating Tumour Cells (CTCs ), which circulate in patient blood 
after being shed from solid tumours, may be useful in enhancing prognostic 
techniques and it has previously been shown in other malignancies that the 
presence of CTCs in patient blood is associated with poor prognosis. In CMM, 
CTCs can be detected through RT-PCR for melanoma associated markers, 
although this technique does not allow CTCs to be quantified. 
In this study, melanoma CTCs were isolated from patient peripheral blood 
samples with a combination of MCSP, MCAM and ABCB5 antibody coupled 
immunomagnetic beads and were subsequently quantified. The 
immunomagnetic bead capture protocol was performed for 21 control and 33 
patient blood samples ranging from clinical stage 0 to IV. Results showed a 
significant difference between the mean number of cells captured from control 
(mean=3. 71) and patient (mean=24.45) blood samples (p=0.01 ). Furthermore, 
there was a significant relationship between the number of MCAM positive 
CTCs and disease stage (r=0.486, p=0.004 ), although there were ·no 
significant relationships between the number of MCSP positive, ABCB5 
positive or total CTCs and disease stage. Overall, this study has identified 
MCAM positivity as a CTC marker associated with disease progression which 
may be useful in improving prognostic testing and disease management in 
melanoma patients. 
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1. Introduction 
Cutaneous Malignant Melanoma (CMM) is a highly aggressive skin cancer which is 
notoriously resistant to currently available cancer therapies. Although CMM only 
accounts for a small percentage of skin cancers, it is responsible for 80% of skin 
cancer related deaths (Lewis et al., 2005). Australia, along with New Zealand, North 
America and Northern Europe, has the highest incidence rate of melanoma 
worldwide (Villanueva & Herlyn, 2009). Disease outcome is largely determined by 
progression at the time of diagnosis. Patients with in-situ melanoma at time of 
detection have a very high probability of relapse free survival following surgical 
resection of the primary tumour, whereas those with metastatic disease at time of 
detection have poor prognosis. Currently available prognostic techniques, including 
primary tumour thickness and detection of metastasis in regional lymph nodes, have 
proved to be inadequate as 30% of patients with in situ melanoma (Koyanagi et al., 
2005a) and 15% of patients with negative lymph nodes at the time of surgical 
'intervention (Jack et al., 2006; Weight et al., 2006) go on to develop metastatic 
disease. 
It is thought that the number of melanoma cells circulating in patient peripheral blood 
may be a useful prognostic measure although, at this time, circulating cells have not 
been effectively quantified in patients across all stages of disease. The presence of 
circulating melanoma cells can be detected by reverse-transcriptase polymerase 
chain reaction (RT-PCR) of melanoma associated markers in patient blood and 
results of previous studies have shown that detection of these markers correlates 
with poor prognosis (Arenberger et al., 2008; Hoon et al., 1995; Hoon et al., 2000; 
Koyanagi et al., 2005a; Lewis et al., 2005; Reynolds et al. 2003). This technique has 
demonstrated that circulating cells are present in peripheral blood of patients across 
clinical stages I to IV, even though there is no clinical evidence of metastasis in 
stage I and II patients (Hoon et al., 1995; Hoon et al., 2000; Koyanagi et al., 2005a). 
The fact that many stage 0, I and II patients later develop metastatic disease, even 
years after surgical intervention, suggests circulating tumour cells are involved in the 
formation of metastases and may therefore be useful in evaluating prognosis in early 
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stage patients. The major limitation of RT -PCR detection of circulating cell markers is 
that it does not allow circulating cells to be quantified. 
In order to quantify circulating melanoma cells it is first necessary to isolate them 
from patient blood samples. Currently, the most promising method of isolating 
circulating melanoma cells is by immunomagnetic bead capture, where cells are 
targeted specifically by magnetic beads bound to melanoma antigen specific 
antibodies. This technique has been shown to be effective at isolating circulating 
melanoma cells (Faye et al., 2004; Kitago et al. 2009; Ulmer et al., 2004), although 
cells have not been able to be isolated in all tested patients. In this study, a 
combination of Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP), 
Melanoma Cell Adhesion Molecule (MCAM) and ATP-Binding Cassette Subfamily 8 
Member 5 (ABCBS) antibodies coupled to immunomagnetic beads were used for 
optimal isolation and subsequent quantification of circulating melanoma cells from 
patients of American Joint Committee on Cancer (AJCC) stages 0 to IV, in order to 
'determine the relationship between the number of melanoma circulating cells and 
disease stage. 
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2. Literature Review 
2.1. Cutaneous Malignant Melanoma 
Cutaneous Malignant Melanoma is a highly aggressive and drug resistant form of 
skin cancer. Melanoma arises from melanocytes, the melanin pigment producing 
cells of the skin, which are of neuroectodermal origin (Fiorenes et al., 1994). During 
embryogenesis, pluripotent cells of the neural crest migrate to the skin, hair and eyes 
where they differentiate into melanocytes capable of producing melanin (Goding, 
2007). Melanoma only accounts for 4% of skin cancers although it is responsible for 
80% of skin cancer related deaths (Lewis et al., 2005). Australia, New Zealand, 
North America and Northern Europe have the highest incidence of melanoma 
worldwide (Villanueva & Herlyn, 2009). In Western Australia, melanoma has the 
highest incidence of any cancer in both males and females aged 15 to 39 {Threlfall & 
Thompson, 2009). Survival of the disease is largely dependent on progression at 
time of detection, particularly the extent of metastasis. Current prognostic techniques 
and treatments are ineffective at managing the disease and unless diagnosis and 
treatment occurs before the onset of metastasis, prognosis is extremely poor. 
2.2. Melanoma Development 
Melanomas can originate from existing naevi, circular areas of dark pigmentation on 
the skin, or can arise spontaneously (Tan, 201 0). The most common cause of 
melanoma is excessive exposure to ultraviolet (UV) radiation, with both UVA and 
UVB wavelengths being implicated (Leiter & Garbe, 2008; Villanueva & Herlyn, 
2009). Initially, melanocyte~ undergo proliferation resulting in the formation of benign 
naevi which may or may not progress to radial growth phase melanomas. 
Melanomas undergo two growth phases, a radial growth phase (RGP) where growth 
is superficial within the epidermis and a vertical growth phase (VGP) where the 
tumour increases in thickness invading deeper tissue layers (Fig 2.1.). Once the 
lesion has entered the vertical growth phase it becomes capable of metastasis as a 
result of invasion of subcutaneous tissue and entry into lymphatic and circulatory 
vessels (Fig 2.2.). Studies have shown that vertical growth phase cells are capable 
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of tumour formation when injected into immunodeficient mice (Villanueva & Herlyn, 
2009). 
Melanocyte Differentiated 
precursor melanocyte 
Fibroblasts -Endothelial-Immune 
cells cell5 
Tumour m icroe nvi ron me nt 
Figure 2.1. Typical pathway of melanoma development (Villanueva & Herlyn, 2009) 
Primary tumour thickness is used as a prognostic indicator as increased thickness is 
associated with an increased number of metastases. Clinically, a tumour is regarded 
as thin if it is less than one millimetre in thickness, moderate if between one and four 
millimetres in thickness and thick if it is greater than four millimetres in thickness 
(Tan, 201 0). Patients with a primary tumour thickness of less than 0.75mm have a 
95% cure rate while patients with a primary tumour greater than 4mm in thickness 
have a cure rate of 20-25% (Breslow, 1970; Kerbel, 1990). 
Figure 2.2. Diagram illustrating the ability of tumours to metastasise via the circulatory system 
(Pantel et al., 1999) 
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2.3. Mutations 
The development of melanoma is multifactorial although, as mentioned previously, 
the major cause is excessive exposure to UV radiation. Melanocytes are normally 
under the control of adjacent keratinocytes which release chemical signals regulating 
proliferation and cell-cell adhesion, however, altered expression of regulating genes 
can result in uncontrolled proliferation and detachment of melanocytes (Haas et al., 
2005). Approximately 1 0% of melanomas appear in genetically predisposed 
individuals, that is individuals with fair skin, increased freckling and red hair and a 
further 10% of cases are familial, appearing in individuals with a family history of the 
disease (Villanueva & Herlyn, 2009). Individuals with a large number of atypical or 
dysplastic nevi are also at greater risk of developing melanoma. There are a number 
of pathways and mutations associated with melanoma development. Genetic 
predisposition can be the result of polymorphisms in the Melanocortin-1 Receptor 
(MC1 R) gene which are associated with red hair, fair skin and freckling (Villanueva & 
Herlyn, 2009). Inherited mutations in the CDKN2A and CDK4 genes are associated 
with familial melanoma, with CDKN2A mutations being the most frequent. CDK4 
mutations are also regularly seen in sporadic melanomas where, like the majority of 
melanoma associated mutations, they develop spontaneously (Villanueva & Herlyn, 
2009). 
Other sporadic mutations commonly found in melanomas occur in oncogenes. 
Oncogenes, which in their normal form (proto-oncogenes) regulate cell proliferation, 
promote uncontrolled cell division contributing to tumour formation. The most 
common oncogene implicated in melanoma formation is BRAF, which is mutated in 
approximately 60% of naevi and melanomas (Davies et al., 2002). BRAF mutations 
cause constitutive activation of the MAPK pathway resulting in increased cell 
proliferation and survival contributing to melanoma formation (Sumimoto et al., 
2006). Mutations in the NRAS oncogene, which are seen in 10-20% of melanomas, 
also activate the MAPK pathway (Marks & Neill, 2008, p. 149). BRAF and NRAS 
mutations are mutually exclusive suggesting they have similar roles in uncontrolled 
melanocyte proliferation leading to melanoma development (Villanueva & Herlyn, 
2009). 
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2.4. Diagnosis and Treatment 
Initial diagnosis of melanoma is made using the ABCDE system to determine 
whether a lesion is likely to be a melanoma. Using this system, a lesion may be a 
melanoma if it is asymmetrical, has an irregular border, uneven colouring, a diameter 
greater than 6mm and is evolving or changing over time (Tan, 201 0) (Fig 2.3.). If a 
lesion is diagnosed as a melanoma it will be surgically resected with surrounding 
tissue in order to remove as many malignant cells as possible (Urist, 1996). The 
amount of surrounding tissue excised is based on the thickness of the tumour (Jack 
et al., 2006). 
Figure 2.3. A typical example of superficial spreading melanoma depicting asymmetry, irregular 
border and uneven colouring (Ada County, n.d.) . 
If the patient has metastatic disease at the time of removal of the primary tumour 
prognosis is less favourable (Wascher et al., 2003). Usually if the tumour is greater 
than 0.75 millimetres in thickness or is ulcerated, the sentinel lymph node, which is 
the first node to receive drainage from a primary tumour and the most common first 
site of metastasis (Goto et al., 2008), will be examined for involvement and can be 
surgically removed if there is evidence of metastasis. If the sentinel node is 
metastatic, this process will be repeated in other regional nodes (Krag et al., 1995). 
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Surgical removal of secondary tumours is regularly undertaken in patients where 
metastasis is more distant than regional lymph nodes (Tan, 201 0). If metastasis is 
extensive, chemotherapy, immunotherapy, interferon therapy or radiotherapy may be 
considered although melanoma is notoriously resistant to these treatments. Of these, 
the most successful therapies have proven to be immunotherapy with interleukin-2 
and interferon therapy with interferon-alpha, however patient responses vary 
considerably and the toxicity of these treatments is high (Steen et al., 2008). The 
only chemotherapeutic agent currently approved for the treatment of metastatic 
melanoma by the US Food and Drug Administration is dacarbazine, which is often 
used in conjunction with other therapies (Biesa et al., 2009). 
A number of targeted therapies have been trialed for use in the treatment of 
metastatic melanoma in order to specifically inhibit melanoma growth with the intent 
of increasing treatment efficacy while eluding the adverse effects of more general 
cancer therapies. The use of mutant BRAF inhibitors showed particular promise in 
this area (Shepherd et al., 201 0) although initial success of trials applying this 
treatment have since been tempered by indications of resistance to this therapy 
(Fisher et al., 201 0; Flaherty et al., 201 0; Modjtahedi & Essapen, 2009). 
2.5. Staging 
It is important to accurately stage melanoma in order to determine prognosis and 
establish the best possible strategy for treating the disease. Staging of the disease is 
based on thickness of the primary tumour, the presence of ulceration and the extent 
of metastasis. The most widely used staging system for melanoma is that instigated 
by the American Joint Committee on Cancer (AJCC). Stages range from 0 to 4, 
where 0 describes a primary tumour in situ and 4 describes patients with extensive 
metastasis. Within these stages there are many sub-stages describing primary 
tumour thicknesses and specific sites and types of metastases; these are grouped 
into stages 0, 1A, 1 B, 2A, 28, 2C, 3 and 4 (American Joint Committee on Cancer, 
2002) (Table 2.1.). Stage 1A melanoma is associated with a five-year survival rate of 
95% whereas stage 4 melanoma is associated with a five-year survival rate of 7 to 
19% depending on the number and location of metastases {Tan, 201 0). Stage 4 
7 
patients can be further subdivided based on their serum lactate dehydrogenase 
(LDH) level. 
Table 2.1. The AJCC Staging System for Melanoma (adapted from American Joint 
Committee on Cancer, 2002) 
Stage 
0 
1A 
18 
2A 
28 
2C 
3 
4 
Description 
Primary tumour in situ 
Primary tumour less than or equal to 1 mm in 
thickness with no ulceration and no evidence 
of metastasis 
Primary tumour less than 1 mm in thickness 
with ulceration but no evidence of metastasis 
OR primary tumour between 1 and 2mm in 
thickness with no ulceration and no evidence 
of metastasis 
Primary tumour between 1 and 2mm in 
thickness with ulceration but no evidence of 
metastasis OR primary tumour between 2 
and 4 mm in thickness with no ulceration and 
no evidence of metastasis 
Primary tumour between 2 and 4mm in 
thickness with ulceration but no evidence of 
metastasis OR primary tumour greater than 
4mm in thickness with no ulceration and no 
evidence of metastasis 
Primary tumour greater than 4mm in 
thickness with ulceration but no evidence of 
metastasis 
Primary tumour any thickness with 
metastasis to one or more regional lymph 
nodes but no distant metastases 
Primary tumour any thickness with distant 
metastasis to skin, subcutaneous tissue, 
lymph nodes, lungs and visceral organs 
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The LDH test allows the extent of metastasis to be determined. The test measures 
the level of serum lactate dehydrogenase (LDH) which increases in response to 
tissue damage, especially to the heart, lungs, liver, kidneys, brain and skeletal 
muscle resulting from invasion of tissues by metastatic tumours (Agarwala et al., 
2009). LDH level is currently the strongest independent prognostic factor in 
advanced metastatic melanoma and therefore proves useful in the postoperative 
monitoring of patients as it is a good predictor of survival (Utikal et al., 2007). If 
serum LDH is elevated, the presence of metastases should be confirmed by CT, 
PET or MRI scans as elevated LDH is not exclusive to metastatic melanoma and can 
also result from muscle injury, liver disease and hypotension (Agarwala et al., 2009). 
It has been found that although elevated serum LDH is strongly associated with poor 
prognosis, there is a weak relationship between LDH level and tumour thickness. It is 
also the case that elevated LDH is not associated with specific sites of metastasis 
which shows that the LDH test should be performed irrespective of tumour size and 
location of metastases. 
2.6. Melanoma Markers 
To further optimise melanoma staging, there has been much recent research aiming 
to identify markers of disease progression. Current research is being undertakefl to 
identify the expression of genes in metastatic cells which can be used to show 
residual disease in clinically disease-free patients. This will provide prognostic 
information in these patients revealing the likelihood of disease relapse (Hoon et al., 
2000). The problem is that as more studies are undertaken, evidence shows that 
malignant melanoma is an extremely heterogeneous disease with patterns of gene 
expression varying considerably between cases and between cells within the same 
tumour (Hoon et al., 2000; Reynolds et al., 2003). However, although there is 
considerable variation within the disease, some genes are seen to be abnormally 
expressed in the majority of cases while others are implicated less frequently. 
Research continues into developing a reliable set of markers for use in profiling of 
the disease. 
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Other research has set out to establish which markers are associated with an 
aggressive phenotype with high metastatic potential as opposed to a less aggressive 
phenotype with low metastatic potential (Bittner et al., 2000; Ryu et al., 2007). 
Identification of these markers would allow the prognosis of early primary tumours to 
be evaluated independent of tumour thickness and before metastasis has occurred. 
Results to date have shown that the expression levels of many genes are altered in 
cells categorised as more aggressive compared with less aggressive cells. Many 
genes involved in cell cycle control, cell proliferation, DNA replication and repair and 
resistance to apoptosis are upregulated in more aggressive cells while many genes 
involved in cell adhesion and melanocyte differentiation are downregulated (Ryu et 
al., 2007). Unfortunately, results of these studies have been inconclusive due to the 
abundance of associated markers which vary considerably between cases resulting 
in a number of different phenotypes being associated with tumour aggressiveness 
(Seftor et al., 2002). It is also unclear whether primary tumour cells that appear to 
have an aggressive phenotype are the same cells responsible for the formation of 
secondary tumours in metastatic disease. 
2.6.1. Types of Markers 
Research has found an abundance of markers associated with melanoma. Thes~ 
markers may be normal melanocyte genes involved with normal melanocyte 
function, markers specific to melanoma which are not expressed in normal 
melanocytes or other tumours or non-specific markers involved with tumour growth 
and development which are expressed in a variety of cancer types (Medic et al., 
2006). As previously mentioned, due to the heterogeneous nature of melanoma 
there are many markers associated with the disease with some being expressed 
more frequently than others. ·For this reason, only those markers detected in a large 
percentage of melanomas showing the greatest promise for use in improving 
diagnostic and prognostic techniques will be discussed. 
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2.6.1.1. Normal Melanocyte Markers 
There are a number of markers associated with melanoma that are expressed in 
both normal melanocytes and melanoma cells. Tyrosinase is an enzyme involved in 
the production of melanin which is commonly used as a marker in melanoma 
diagnosis and prognosis (Osella-Abate et al., 2003; Proebstle et al., 2000; Schmidt 
et al., 2005). Although tyrosinase is expressed in normal melanocytes, its detection 
in patient blood suggests the presence of melanoma cells as normal melanocytes do 
not enter the circulatory system (Steen et al., 2008). 
Microphthalmia-Associated Transcription Factor (MITF) is involved in the 
differentiation of melanocytes during melanocytic development (Loercher et al., 
2005). It is also implicated in the proliferation and development of invasive behaviour 
of melanoma cells (Carreira et al., 2006; Garraway et al., 2005). Due to its role as a 
transcription factor, MITF regulates the expression of many other melanoma 
' 
associated genes, such as MART-1 (Duet al., 2003). 
Tyrosinase-Related Protein-1 (TYRP-1) and Tyrosinase-Related Protein-2 (TYRP-2) 
are both expressed in normal melanocytes and are involved in melanin synthesis 
(Urabe et al., 1993). These genes are also expressed in melanoma cells however 
their expression only provides prognostic information in more advanced stages of the 
disease (Takeuchi et al., 2004). 
2.6.1.2. General Tumour Markers 
A number of markers associated with melanoma are non-specific tumour markers 
expressed in a range of malignancies. Melanoma antigen gene A3 (MAGE-A3) is 
expressed in a variety of cancers including testicular cancer and melanoma, 
however it is not expressed in normal tissue with the exception of some reproductive 
cells such as male gametes and cells of the placenta (Koyanagi et al., 2005a). In 
melanoma, MAGE-A3 is more commonly expressed in early stages of the disease 
(Hoon et al., 2000; Koyanagi et al., 2005a). 
11 
S100 is a group of genes expressed in cells of neural crest origin and several S100 
genes are expressed in neural crest derived tumours, which include melanoma 
(Schmidt et al., 2005). S100p is one S100 marker commonly used to detect 
metastasis in sentinel lymph nodes of melanoma patients (Goto et al., 2008). S100b 
is another S1 00 gene which is not frequently detected in early stage melanomas but 
is commonly detected in later stages of the disease where it corresponds with 
prognosis (Martenson et al., 2001 ). 
2.6.1.3. Melanoma Specific Markers 
Other markers are specific melanoma associated antigens which allow the 
differentiation of melanomas from other cutaneous malignancies. Melanoma Antigen 
Recognised by T cells-1 (MART-1 ), which also has the synonyms MLANA and 
Melan-A, is involved in the formation of melanosomes which are the melanin storing 
organelles contained in melanocytes (Du et al., 2003). MART-1 can be detected in 
peripheral blood of advanced stage patients suggesting its expression is related to 
disease progression and may be useful in predicting patient survival (Koyanagi et al., 
2005a,b). 
Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP), also known as 
High-Molecular Weight Melanoma-Associated Antigen (HMW-MAA), is encoded by 
j the CSPG4 gene (Wang et al., 2004). MCSP is expressed on the surface of 
melanoma cells and is implicated in cell adhesion, proliferation, migration and 
invasion (Yang et al., 2004; Yang et al., 2009). MCSP is uniformly and abundantly 
expressed in the majority of melanomas (Yang et al., 2004). It can further be 
detected in early metastatic cells during subcutaneous invasion (Wang et al., 2004) 
and is therefore a useful marker to target for detection of early metastasis. A study 
by Goto et al. (2008) showed that all sentinel lymph nodes in metastatic melanoma 
patients were positive for MCSP by immunohistochemical staining with MCSP 
antibody. The results also showed that MCSP was more specific and sensitive than 
MART-1 and S100p for detecting sentinel lymph node metastasis, both of which are 
commonly used for this purpose. Other research has shown MCSP is expressed on 
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the surface of circulating melanoma cells as circulating cells have been successfully 
captured using anti-MCSP bound immunomagnetic beads (Kitago et al. 2009; Ulmer 
et al., 2004 ). 
Melanoma Cell Adhesion Molecule (MCAM), also known as MUC-18 and CD146, is 
a cell surface melanoma marker encoded by the MCAM gene (Wang et al., 2004 ). 
The sequence of MCAM is similar to the neural cell adhesion molecules of the 
immunoglobulin superfamily, which are involved in organogenesis during 
development (Lehmann et al., 1989). This suggests that MCAM is normally involved 
in intercellular adhesion and may also be developmentally regulated. It has been 
observed that MCAM is downregulated in normal melanocytes and the majority of 
early melanomas probably due to cell-cell contact with neighbouring keratinocytes 
(Shih et al., 1994). Low level expression is seen in early melanomas, which is 
thought to be due to escaped control of keratinocytes, and high level expression is 
observed in late stage melanomas due to constitutive activation of the MCAM gene. 
MCAM is constitutively expressed in 70% of metastatic melanomas with amplified 
expression associated with increased tumour thickness and aggressive invasive 
behaviour (Mangahas et al., 2004; Medic & Ziman, 201 0). Studies have shown 
MCAM is frequently detected in multi-marker qRT -PCR assays of patient peripheral 
blood and its expression is strongly related to disease progression (Hoon et al., 
2000). 
2. 7. Melanoma Stem Cells 
Recent research has identified melanoma stem cells capable of self renewal and 
differentiation which may lead to tumourigenesis (Boiko et al., 201 0; Sekulic et al., 
2008). It is thought that proliferation of these highly resistant cells after treatment 
may result in disease relapse (Fig 2.4.). Similar cells have been identified in other 
malignancies and it is thought they may play a significant role in tumour maintenance 
in those tumours which are notoriously difficult to treat. It has been observed that 
normal stem cells show a great deal more resistance to toxic treatments such as 
chemotherapy and radiotherapy than their differentiated descendants (Sekulic et al., 
2008). The idea that melanomas arise from tumorigenic stem cells is further hinted at 
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by the heterogenic nature of the disease which suggests tumours originate from cells 
capable of multi-lineage differentiation (Fang et al., 2005). 
Melanoma stem cell 
Self-
renewal ! Tumor growth 
! 
! 
Daughter cell death 
Melanoma stem cell 
survives 
Tumor relapse with 
new daughter cells 
Figure 2.4. The proposed capability of melanoma stem cells for tumour maintenance and renewal 
(Sekulic et al., 2008) 
A sub-population of melanoma stem cells express ATP-Binding Cassette Subfamily 
B Member 5 (ABCB5) on their surface. ABCB5 is actively involved in removing toxic 
substances, such as chemotherapeutic agents, from these cells (Chen et al., 2005). 
It has been shown that ABCB5 positive cells have greater tumourigenic capacity as 
well as a greater ability for renewal and differentiation than ABCB5 negative cells. 
The possible role of ABCB5 positive stem cells in tumour growth was shown by 
Schatton et al. (2008) who demonstrated inhibited tumour growth in mice that 
underwent treatment targeting ABCB5 positive cells. If the role of these stem cells in 
tumour formation is established and their presence among circulating cells is 
confirmed, approaches to treatment would be significantly influenced as these highly 
resistant cells would need to be targeted concurrently with the general tumour cell 
population in order to reduce the chance of disease relapse. 
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2.8. Circulating Tumour Cells 
More recently, research has been conducted to measure markers of circulating 
melanoma cells in patient blood. The rationale of this is that previous studies have 
shown circulating tumour cells are often present in the circulation of cancer patients 
and are associated with tumour progression (Steen et al., 2008). It is estimated that 
on average, tumour cells circulate in the blood at a concentration of one per 106 to 
107 normal cells (Krivacic et al., 2004). Due to the ability of circulating tumour cells to 
form metastases, their detection may identify patients with a greater risk of disease 
relapse significantly earlier than methodologies for the detection of secondary 
tumours or residual disease, which is currently undetectable at early stages 
(Reynolds et al., 2003). Because of this, it is thought that circulating melanoma cells 
may be a good measure of prognosis and may be able to guide treatment of the 
disease (Hoon et al., 2000; Steen et al., 2008; Ulmer et al., 2004). Current 
prognostic techniques, including measuring primary tumour thickness and sentinel 
lymph node examination, are unable to adequately guide treatment and it is thought 
that the detection of circulating melanoma cells may provide information that can be 
monitored to establish treatment strategies and determine their efficacy. 
Furthermore, these prognostic tests are unable to identify many early stage patients 
requiring treatment as a significant number of non-metastatic patients who are 
clinically disease free following surgery later develop metastatic disease. It has bee·n 
suggested that approximately 30% of in situ patients (Koyanagi et al., 2005a) and 
15% of patients with no evidence of lymph node metastasis (Jack et al., 2006; 
Weight et al., 2006) at the time of surgical intervention subsequently develop 
metastases. Quantifying circulating cells in early stage patients may therefore be 
useful in identifying those patients at risk of disease relapse who may benefit from 
some form of treatment. 
2.8.1. qRT-PCR Detection of Markers 
Early methods of detecting circulating tumour cells in patient blood involved the 
automated scanning of blood samples in order to identify labelled cells, however 
these methods were extremely time consuming. Quantitative Real-Time Polymerase 
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Chain Reaction (qRT-PCR) has allowed marker mRNA transcripts in circulating 
melanoma cells to be detected in patient peripheral blood samples suggesting the 
presence of circulating melanoma cells (Arenberger et al., 2008; Hoon et al., 1995; 
Hoon et al., 2000; Koyanagi et al., 2005a; Lewis et al., 2005; Reynolds et al. 2003). 
This technique can detect markers in extremely small quantities and far more rapidly 
than previous methods due to its sensitivity and efficiency. It has been shown that 
qRT-PCR can detect RNA from one malignant cell in 10A7 normal background cells 
which is sufficiently sensitive to detect low numbers of circulating tumour cells (Lewis 
et al., 2005). Furthermore, many studies have detected markers in peripheral blood 
of AJCC stage I and II patients who have no evidence of metastasis, suggesting the 
presence of circulating melanoma cells even in early stages of the disease (Hoon et 
al., 1995; Hoon et al., 2000; Koyanagi et al., 2005a). 
It has been shown that circulating tumour cells can be detected in patient peripheral 
blood using a single marker qRT-PCR assay (Proebstle et al., 2000; Stoitchkov et 
al., 2001 ), although more recent studies have aimed to develop a suitable multi-
marker assay to increase the sensitivity of the test and thus increase rates of 
detection. The reason for the requirement of a multi-marker assay is due to the 
heterogeneous nature of melanoma, which causes variability of marker expression 
between cells meaning not all cells will be detected by RT-PCR of a single mRNA 
transcript (Hoon et al., 2000). Studies employing multi-marker qRT-PCR assays 
have shown they offer a higher detection rate than single marker assays (Hoon et 
al., 1995; Koyanagi et al., 2005a; Reynolds et al. 2003), however a standard multi-
/marker assay has yet to be developed. 
Research has shown, however, that there are many limitations to this technique. Due 
to the heterogeneous nature of melanoma, marker expression can vary considerably 
between patients and even within the same patient (Steen et al., 2008) resulting in 
the possibility of false negatives as the genes being targeted may not be expressed 
or may not be undergoing transcription at the time blood is obtained. One particular 
study showed that patients may be positive or negative for certain melanoma 
markers at different times of the day depending on the time blood samples were 
taken (Keilholz et al., 2004 ). Some studies have also reported a number of false 
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positives where control blood samples appear positive for particular melanoma 
markers. This could be due to inadequate specificity of the test, epithelial cell 
contamination of blood samples or simple issues of quality control (Steen et al., 
2008). In addition to specificity issues, some studies have shown this technique to be 
inadequately sensitive, reporting detection of markers by qRT-PCR in fewer than 
50% of stage IV patients with advanced metastatic disease (Mocellin et al., 2004). 
2.8.2. Circulating Cells: Quantity vs. Phenotype 
Although qRT-PCR shows circulating cells are present in patient blood, via the 
detection of melanoma markers, it does not allow them to be quantified. A suitable 
method allowing the quantification of circulating cells in patients at different clinical 
stages of melanoma would be valuable as it will help to reveal the relationship 
between CTC numbers and disease prognosis. At this point in time the influence of 
quantity and phenotype of circulating cells on prognosis is largely unknown with 
current research producing conflicting evidence. Some studies have shown that an 
increase in circulating cell numbers appears to correlate negatively with survival 
(Steen et al., 2008; Ulmer et al., 2004); although these studies are far from definitive 
as circulating cells were unable to be captured in many patients tested. Furthermore, 
some evidence suggests cells with tumourigenic potential, based on their phenotype, 
are rare (Boiko et al., 201 0), whereas others argue that the majority of melanoma 
cells may be capable of tumour formation (Quintana et al., 2008). If an increase in 
circulating cell numbers is found to correlate with more advanced disease stage, 
circulating cell numbers could be used as a measure of disease progression to 
)prove prognostic testing. 
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2.9. lmmunomagnetic Bead Capture 
Currently, immunomagnetic bead capture is one of the most promising methods of 
isolating circulating tumour cells from patient peripheral blood samples (Steen et al., 
2008). lmmunomagnetic beads, when coupled with antibody, allow for the isolation 
of specific cells within a sample as the antibody-bead ligand is allowed to bind to the 
cell type of interest which can then be isolated from the sample with the use of a 
magnet (Fig 2.5.). 
Figure 2.5. The principle of isolating CTCs through immunomagnetic enrichment. (Adnagen, n.d.) 
Magnetic beads are coupled with antibody which bind CTCs in patient peripheral blood. CTCs 
can subsequently be isolated from the sample using a magnet. 
A number of studies have provided evidence showing isolation of melanoma cells 
from patient peripheral blood via immunomagnetic bead capture is successful (Faye 
et al., 2004; Kitago et al. 2009; Ulmer et al., 2004). In order for immunomagnetic 
beads to capture circulating tumour cells they must be able to bind a minimum of one 
cell per 106 background cells otherwise low numbers of circulating cells would not be 
able to be captured (Krivacic et al., 2004). The results of blood spiking experiments, 
where single melanoma cells have been added to control blood samples to 
demonstrate the detection limit of antibody-coupled beads, have shown that these 
beads are sensitive enough to bind low concentrations of circulating tumour cells. 
For example, a study by Faye et al. (2004) showed that anti-MCSP coupled 
immunomagnetic beads were able to bind a single melanoma cell in a sample 
containing 107 normal blood cells. A similar spiking experiment by Kitago et al. 
(2009) demonstrated their anti-MCSP beads were able to bind one melanoma cell in 
5x1 0"6 blood cells. These results show that immunomagnetic bead capture is a 
sensitive enough method to isolate low quantities of circulating melanoma cells. 
18 
The CeiiSearch system uses EpCAM antibody bound immunomagnetic beads to 
isolate circulating tumour cells in a number of malignancies of epithelial origin (Steen 
et al., 2008). This system has been used successfully to isolate circulating cells from 
peripheral blood in breast cancer patients and was tested in stage Ill and IV 
melanoma patients as circulating melanoma cells are known to be positive for 
EpCAM. The results showed that circulating cell numbers appeared to correlate with 
survival as an increased number of circulating cells was associated with a decreased 
survival time. However, the anti-EpCAM beads were only able to capture circulating 
cells in some of the stage IV patients included in the study. As the marker used in 
this assay is not melanoma specific, the use of immunomagnetic beads bound to 
melanoma specific antibodies may be more successful. 
Studies trialling immunomagnetic bead capture of circulating melanoma cells with 
anti-MCSP coupled beads have provided mixed results. One study was able to 
isolate circulating melanoma cells from 100% of stage IV patients tested (Kitago et 
al.,' 2009), while another was only able to detect circulating cells in 1% of patients 
ranging from stage I to IV; however this study defined captured cells as those bound 
to more than four beads which were detected by microscopy (Faye et al., 2004). A 
study by Ulmer et al. (2004) was able to isolate cells from patients of all AJCC 
stages with anti-MCSP beads, although cells were not detected in all patients; only 
43% of stage IV patients were positive for circulating cells. Also, the number of cells 
captured in patients of each stage varied widely with considerable overlap, possibly 
due to heterogeneous expression, suggesting a combination of antibodies would be 
more effective at capturing cells. Since previous results have only been somewhat 
successful, different combinations of antibodies should be trialled to optimally 
capture circulating melanoma cells in patients at all stages of the disease in order to 
show the difference in quantity and phenotype of early and late stage cells. 
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2.9.1. Suitable Target Antigens 
Due to the mixed success when a single marker was targeted in previous bead 
capture studies, as well as the fact that melanoma is extremely heterogeneous, a 
combination of antibodies was used in this study in order to maximise the chances of 
successfully isolating circulating melanoma cells in patients' at all stages of the 
disease. For an antibody to be suitable for capturing circulating cells it must have a 
number of characteristics. Firstly, the marker for which the antibody is specific must 
be expressed on the surface of melanoma cells. This is to ensure the antibody can 
recognise and bind to the marker which would not be possible if it was expressed 
within the cell. Antibodies should also target markers which are expressed in the 
majority of cells to ensure all circulating cells are captured when used in combination 
with other antibodies. 
MCAM is constitutively expressed on the surface of the majority of advanced stage 
, 
melanoma cells and its expression is strongly related to disease progression 
(Mangahas et al., 2004; Medic & Ziman, 2010; Shih et al., 1994). For this reason, 
MCAM is a suitable marker to target for the isolation of circulating melanoma cells in 
patients of more advanced stages of the disease. The fact that MCAM expression is 
associated with aggressive tumour behaviour also suggests that it is a suitable 
marker to target for the isolation of aggressive cells with high metastatic potential. 
MCSP is expressed on the surface of early stage melanoma cells (Wang et al., 
2004; Yang et al., 2004) and its expression continues throughout all stages of the 
disease (Faye et al., 2004; Goto et al., 2008; Kitago et al., 2009; Ulmer et al., 2004). 
MCSP is therefore a suitable cell surface marker to target for the isolation of early 
stage circulating cells as well as more advanced stage cells which do not express 
MCAM and therefore may have a less aggressive phenotype. As previously 
discussed, it has been suggested that although stage I and II patients do not have 
metastatic disease they may still have circulating tumour cells as peripheral blood of 
these patients has been shown to be positive for a number of melanoma markers by 
qRT-PCR (Hoon et al., 1995; Hoon et al., 2000; Koyanagi et al., 2005a). 
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Lastly, ABCB5 is expressed on the surface of a subset of melanoma stem cells 
which have greater tumourigenic capability than ABCB5 negative melanoma stem 
cells (Chen et al., 2005). ABCB5 antibody can therefore be used to isolate circulating 
ABCB5 positive melanoma stem cells which are thought to be implicated in disease 
relapse following treatment (Chen et al., 2005; Sekulic et al., 2008). Currently, no 
studies have shown melanoma stem cells in patient circulation although unpublished 
results from our laboratory have shown many patient blood samples are positive for 
ABCB5 by qRT -PCR. 
2.9.2. lmmunomagnetic Bead Capture in other Malignancies 
The use of immunomagnetic bead capture to isolate circulating tumour cells in other 
malignancies, including those of the prostate and colon, has been investigated for 
some time. This technique is most commonly used however, and has provided the 
most success, in breast cancer patients. Many studies have provided evidence that 
this method is successful and have shown that the presence of circulating cells 
correlates with poor prognosis (Austrup et al., 2000; Cristofanilli et al., 2004; Raynor 
et al., 2009; Tewes et al., 2009). The use of this technique in breast cancer patients 
has proven to be both more sensitive and specific at detecting circulating cells than 
qRT-PCR (Bossolasco et al., 2002; Martin et al., 2001; Witzig et al., 2002) and 
metastatic cells circulating at 1 in 106 -107 background cells can be consistently 
captured (Reuben et al., 2008). A study by Raynor et al. (2009) used 
immunomagnetic bead capture to isolate circulating cells from patient blood and 
subsequently used a multi-marker qRT-PCR assay on isolated cell RNA to detect 
tumour associated markers. The results of this study showed the number of patients 
positive for at least one marker increased with both disease stage and primary 
tumour thickness. Another. study showed that patients positive for circulating cells 
had shorter overall survival than those classified as negative, where a patient was 
considered positive if they had five or more circulating cells per 7 .5ml of blood 
(Cristofanilli et al., 2004). Quantification of circulating cells has also shown success 
at monitoring patient responses to treatment; specifically an increase in circulating 
cells at treatment completion predicts early relapse of the disease (Lobodasch et al., 
2007; Pachmann et al., 2008; Pachmann et al., 2005). 
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The success of this method has led to its clinical use with the CeiiSearch system 
being approved by the US Food and Drug Administration for the detection of 
circulating cells in patients with metastatic carcinoma of the breast (Reuben et al., 
2008). The reason for the greater success of this technique in breast cancer patients 
compared with melanoma patients is likely due to the trialling of different 
combinations of antibodies to capture circulating cells which has led to the 
development of many breast cancer tests, such as the AdnaTest (Adnagen), which 
target a combination of cell surface markers. Studies trialling this technique in 
melanoma patients have targeted single markers only going as far as testing a 
combination of clones of an antibody to isolate circulating cells (Kitago et al. 2009). 
Both carcinoma of the breast and melanoma are heterogeneous and for this reason 
the use of multiple antibodies proposed in this study may increase the success of 
this technique in melanoma. 
Overall, the use of this technique in breast cancer patients has demonstrated 
circulating cells are an independent predictor of survival of greater value than 
standard prognostic measures (Reuben et al., 2008). This shows that isolation of 
circulating cells by immunomagnetic bead capture is useful for determining patient 
prognosis and with further investigation this technique has the potential to be 
similarly applied in the clinical testing of melanoma patients. 
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3. Summary and Theoretical Framework 
The development of an immunomagnetic bead capture assay using antibodies able 
to effectively bind melanoma cells of all disease stages will provide a suitable 
method of isolating circulating melanoma cells. This technique will have advantages 
over the use of RT-PCR, which can only detect the presence of circulating cells, by 
allowing circulating cells to be captured and quantified. This will reveal the prognostic 
significance of circulating cell numbers which has not yet been determined. If it is 
found that circulating cell numbers correlate strongly with prognosis, i.e. circulating 
cell numbers increase with increased disease stage, this technique could be used 
routinely as a prognostic measure in combination with other available measures, 
such as primary tumour thickness. If this is the case, quantification of circulating cells 
could also be used as a measure of treatment efficacy. For example, the number of 
circulating melanoma cells in a patient undergoing therapy could be continually 
measured to determine whether the treatment is effective, i.e. whether it is reducing 
the number of circulating cells. This would allow the effectiveness of multiple 
treatments on individual patients to be determined. 
As well as the quantification of circulating cells, this technique would allow 
phenotypic analysis of captured cells to be performed in further studies in order to 
characterise circulating cells of different disease stages. This would allow phenotypic 
differences between early and late stage cells to be determined, ultimately revealing 
the influence of circulating cell phenotype on prognosis. 
In this study, MCSP, MCAM and ABCB5 antibody coupled immunomagnetic beads 
were used to isolate and subsequently quantify circulating melanoma cells from 
patient peripheral blood samples across all disease stages in order to determine a 
relationship between the number of circulating cells and disease stage. 
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4. Hypothesis and Aims 
4.1. Hypothesis 
The number of circulating melanoma cells in patient peripheral blood correlates with 
disease stage. 
4.2. Aims 
The overall aim of this research project is to isolate and quantify circulating 
melanoma cells in patient peripheral blood in order to determine the relationship 
between the number of CTCs and disease stage. This will be achieved by: 
1) Checking for marker expression in melanoma cell line and tissue sections of 
pifferent stages to determine the suitability of chosen antibodies to isolate 
circulating melanoma cells. 
2) Manufacturing and testing MCSP, MCAM and ABCB5 antibody coupled 
immunomagnetic beads. 
3) Isolating circulating melanoma cells from patient peripheral blood samples. 
4) Quantifying total circulating cells relative to disease stage. 
5) Quantifying MCSP, MCAM and ABCB5 positive circulating cells relative to 
disease stage. 
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5. Materials and Methods 
5.1. Antibodies 
5.1.1. MCAM 
The MCAM antibody used for cell immunofluorescence and immunomagnetic 
bead coupling was mouse monoclonal anti-human CD146, isotype lgG1 kappa, 
at a concentration of 0.5mg/ml, sourced from BD Biosciences (San Diego, USA). 
The MCAM antibody used for tissue immunohistochemistry was rabbit 
monoclonal anti-human CD146, isotype lgG, sourced from Abeam (Cambridge, 
USA). 
5.1.2. MCSP 
The anti-MCSP antibody used for cell immunohistochemistry, tissue 
immunohistochemistry and immunomagnetic bead coupling was mouse 
monoclonal anti-human MCSP clone number 9.2.27, isotype 1Gg2a, at a 
concentration of 0.5mg/ml, sourced from BD Biosciences. 
5.1.3. ABCB5 
The anti-ABCB5 antibody used for immunomagnetic bead coupling was rabbit 
polyclonal anti-human ABCB5 at a concentration of 0.31mg/ml, sourced from 
Rockland lmmunochemicals. The anti-ABCB5 antibody used for flow-cytometry 
was mouse monoclonal anti-human ABCB5, clone number 3C21 012, received 
from Markus Frank, Brigham and Women's Hospital, Harvard Medical School 
(Boston, USA). 
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5.2. Cell lines 
The A2058 melanoma cell line was used to demonstrate marker expression in 
melanoma cells as well as for experimental testing of antibody-coupled 
immunomagnetic beads. This highly invasive malignant melanoma cell line was 
established from a lymph node metastasis of a 43 year old male. HEK293 cells 
(Human Embryonic Kidney 293 cells) were used as a negative control in the 
testing of marker expression and antibody-coupled beads. 
5.3. Blood Samples 
5.3. 1. Patient Samples 
This study was conducted according to the National Statement on Ethical 
,Conduct in Research Involving Humans, approved by the Edith Cowan University 
Human Research Ethics Committee. Patients with clinical disease stages 0 - IV 
were recruited by five Perth based clinicians. Six stage 0 patients, ten stage I 
patients, eight stage II patients, three stage Ill patients and six stage IV patients 
were included in the study. Patients were diagnosed and staged based on clinical 
and pathological data using the AJCC staging system for melanoma (Table 2.1 ). 
Patients with metastatic disease were treated as per standard clinical protocols. 
Participants signed informed consent with the clinician in accordance with 
protocols safeguarding patient rights and were provided with a clinical trial form 
for blood collection. Approximately 4ml of blood was drawn by phlebotomists into 
EDTA tubes, stored refrigerated at pathology centres and collected when 
possible. A clinical registrar recorded patient clinical data in an excel spreadsheet 
kept separate from laboratory results. 
5.3.2. Control Samples 
Control blood for use in experimental testing of immunomagnetic beads was my 
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own or sourced from volunteers and was drawn by a phlebotomist into EDTA 
tubes and used immediately. There were 21 control blood samples used for 
comparison with patient samples, which were obtained from healthy volunteers 
with no previous history of melanoma and drawn by a phlebotomist into EDTA 
tubes and processed within a few hours. The first few millilitres of all blood 
samples collected for this study were discarded in order to avoid epithelial cell 
contamination. 
5.4. Marker Expression in A2058 Melanoma Cell Line 
The expression of MCAM and MCSP in A2058 melanoma cells was 
demonstrated by immunofluorescence. A2058 cells and HEK293 cells, to be 
used as a negative control, were plated onto sterile coverslips at a density of 
5x1 04 cells per coverslip and allowed to adhere overnight. The media was 
removed by aspiration and the coverslips were washed in PBS. The PBS was 
then aspirated and the cells were fixed by a 10 minute room temperature 
incubation in 4% paraformaldehyde. The cells were washed twice with PBS and 
permeabilised by incubation in 0.2% Triton X-100 in PBS for 5 minutes at room 
temperature. The coverslips were then washed three times in 0.2% Triton X-100 
in PBS over 5 minutes. 
The coverslips were incubated at room temperature for 60 minutes with the 
primary antibody solution. Antibodies were diluted 1 in 500 in 0.2% Triton X-100 
in PBS containing 3% BSA. The coverslips were then washed three times in 
0.2% Triton X-100 in PBS over 5 minutes. They were then incubated at room 
temperature for 20 minutes with the secondary antibody (anti-mouse lgG 
conjugated to Alexa Fluor 488), also diluted 1 in 500 in 0.2% Triton X-1 00 in PBS 
containing 3% BSA. Coverslips were again washed three times in 0.2% Triton X-
1 00 in PBS over 5 minutes, drained well and placed onto a drop of mounting 
medium (Prolong Gold antifade reagent, containing DAPI for nuclear staining 
from Invitrogen (Oslo, Norway)) on a microscope slide. The slides were allowed 
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to air dry before viewing by fluorescence microscopy with an epifluorescent 
Olympus BX51 
microscope equipped with an Olympus DP71 camera. 
The demonstration of ABCB5 expression in these cells was attempted using the 
above protocol however staining was negative raising questions regarding the 
suitability of this particular ABCB5 antibody for immunofluorescence. Instead, 
flow-cytometry was used in order to demonstrate ABCB5 expression in A2058 
cells. 
5.5. Flow Cytometry 
A2058 cells were harvested with media containing EDTA (2mM EDTA in DMEM 
media) and resuspended in 1Om I of DMEM media containing 10% FBS. 0.5ml 
was counted on the Vi-Ceii-XR Cell Viability Analyser (Beckman Coulter, Brea, 
USA) and the appropriate volume containing approximately 500,000 cells was 
dispensed into each of 4 tubes. The cells were pelleted at 2000rpm for 5 minutes 
and the media was removed. The pellets were washed in 500!-11 of MACS buffer 
(2mM EDTA, 0.5% BSA in PBS, pH 7.2) (Miltenyi, Bergisch Gladbach, 
Germany), pelleted again and the supernatants were aspirated to remove any 
remaining media. The pellets were then resuspended in 5001JI of MACS buffer. 
Two tubes were incubated with primary antibody, one with ABCB5 antibody 
(1/500) and another with MCSP antibody conjugated toPE (1/500), for 20 
minutes at room temperature. The cells were then pelleted, the supernatant was 
aspirated and the pellet was resuspended in 5001JI of MACS buffer. The tube 
containing ABCB5 antibody and one tube without a primary were both incubated 
with secondary antibody (anti-mouse lgG conjugated to Alexa Fluor 488) for 20 
minutes at room temperature. The tubes were then centrifuged at 2000rpm for 5 
minutes, the supernatant was removed and the pellets were resuspended in 
5001JI of MACS buffer. These samples were then run on a Gallios Flow 
Cytometer (Beckman Coulter). Cells were separated by side and forward scatter 
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and antibody staining was detected by analysis of fluorescence emission of cells 
where positive cells had increased fluorescence as a result of antibody 
conjugated fluorochromes. 
5.6. Marker Expression in Paraffin Embedded Melanoma Tissue Sections 
The expression of MCSP and MCAM in sections of early and late stage 
melanoma tissue was demonstrated by immunofluorescence. Three sections 
each of in situ, invasive primary and metastatic melanomas were stained with 
MCSP and MCAM antibodies in order to determine the extent of expression of 
these genes in different stages of the disease. Demonstration of ABCB5 
expression was not attempted in tissue sections due to the extremely limited 
quantity of antibody available and the inability to demonstrate ABCB5 expression 
in A2058 cells by immunofluorescence. 
5.6.1. MCAM Staining 
Paraffin embedded tissue sections on glass slides were dewaxed by incubation 
at 58°C for 20 minutes followed by a series of wash steps through xylene, 
ethanol and distilled water. Antigen retrieval was performed with EDT A/Tris 
buffer, pH 8.0, by three 5 minute cycles in a microwave set at 50% power 
(approximately 750 watts). Slides were then cooled in a cold water bath for 20 
minutes, briefly dried and marked with a pap pen. Slides were then washed with 
PBS three times for 5 minutes. Protein blocking was performed by 1 hour 
incubation at room temperature with 10% normal goat serum (NGS) in PBST 
(0.2% Triton X-100 in PBS, pH7.4). The protein blocking solution was poured off 
and the slides were then incubated with primary antibody solution (rabbit anti-
human MCAM diluted 1 in 500 in PBST containing 1% NGS) for 1 hour at room 
temperature. Following this, slides were kept overnight in PBS at 4°C. 
Slides were allowed to reach room temperature and were washed with PBS three 
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times for 5 minutes. Sections were then incubated with secondary antibody 
solution (anti-rabbit lgG conjugated to Alexa Fluor 488 diluted 1 in 500 in PBST 
containing 1% NGS and Hoechst 1 in 50,000) for 1 hour at room temperature. 
PBS was pipetted onto the slides to remove the antibody solution and slides 
were subsequently washed in PBS for 1 hour, changing the PBS every 10 
minutes. Slides were then mounted while still wet with a drop of Fluorsave 
Reagent (Calbiochem, San Diego, USA) and were allowed to dry before viewing 
by fluorescence microscopy with a drop of Prolong Gold anti-fade reagent 
containing DAPI (Invitrogen), as described in 5.8.This method was previously 
described in Medic and Ziman (2010). 
5.6.2. MCSP Staining 
The above method proved unsatisfactory for MCSP staining so a suitable 
'protocol was optimised specifically for this antibody. Optimal results for MCSP 
staining were achieved by following the same protocol as described in 5.6.1., 
although primary antibody concentration and incubation time was altered. 
Primary antibody (mouse anti-human MCSP) was diluted 1 in 20, in PBST 
containing 1% NGS and incubated overnight at 4°C. The remaining portion of the 
protocol was identical to that described in 5.6.1. 
For both MCAM and MCSP staining, positive and negative controls were used to 
confirm positive staining within tissue sections. Paraffin-embedded A2058 cells 
were used as a positive control and sections stained with secondary antibody 
only were used as negative controls. 
5. 7. Antibody-Bead Coupling 
MCAM, MCSP and ABCB5 antibodies were bound to immunomagnetic beads 
using the Dynabeads Antibody Coupling Kit (Invitrogen). This kit contained 
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Dynabeads M-270 Epoxy beads, coupling solutions ('C1' and 'C2'), wash buffers 
('LB' and 'HB') and storage buffer ('SB'). 
It was decided to use 1 01Jg of antibody per mg of beads for optimal antibody-
bead coupling, based on manufacturer's suggestions. Three volumes of 
Dynabead M-270 Epoxy beads were weighed out, one for each antibody, and 
were washed by vortexing in 1 ml of C1 solution. The washed beads were then 
collected by a magnet and the supernatant was removed. The appropriate 
volumes of C1, as indicated in the kit instructions, were added to the beads along 
with the corresponding volumes of each antibody and the resulting solutions 
were mixed by vortexing. The appropriate volumes of C2 were added and the 
solutions were again mixed by vortexing. The antibody-bead solutions were 
incubated on a roller at 37°C overnight to allow binding. The antibody coupled 
beads were collected on a magnet and the supernatant was removed. The beads 
~hen underwent a series of washes described in the manufacturer's instructions 
and were finally resuspended in storage buffer and stored at 4°C until use. 
5.8. Testing Antibody-Coupled Beads on A2058 Cells 
A2058 cells were harvested with accutase and resuspended in 1Om I DMEM 
media containing 10% FBS. 0.5ml was counted on the Vi-Ceii-XR Cell Viability 
Analyser (Beckman Coulter) and the appropriate volume containing 
approximately 500,000 cells was added to each of 3 tubes. 11-11 of beads was 
added to each tube, one bead type per tube, and tubes were then incubated for 
30 minutes at 4°C on a roller to allow binding. Tubes were placed on a magnet to 
collect the bead bound cells and the supernatant was removed. The beads were 
washed 3 times in 1ml MACS buffer (2mM EDTA, 0.5% BSA in PBS, pH 7.2), 
resuspended in 1 001-JI MACS buffer and pi petted onto coverslips on a magnet. 
The liquid was aspirated and the coverslips were allowed to dry before being 
mounted onto microscope slides with a drop of Prolong Gold anti-fade reagent 
containing DAPI (Invitrogen). 
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5.9. Bead Capacity 
A2058 and HEK293 cells were harvested with accutase and counted on the Vi-
Ceii-XR Cell Viability Analyser (Beckman Coulter). The volume containing 
approximately 500,000 cells was calculated for each cell type and added to 6 
tubes, 3 containing A2058 cells and 3 containing HEK293 cells. The cells were 
pelleted at 2000rpm for 5 minutes, the supernatants were removed and the 
pellets were washed in 1ml MACS buffer (2mM EDTA, 0.5% BSA in PBS, pH 
7.2). The solutions were then centrifuged again, the supernatants were discarded 
and the pellets were resuspended in 1 ml MACS buffer. 11JI of beads was then 
added to each tube, each bead type being added to one tube of A2058 and one 
tube of HEK293 cells. The tubes were then incubated on a roller for 30 minutes 
at 4°C. 
' Tubes were placed on a magnet to collect the beads and washed 5 times with 
MACS buffer. The beads were resuspended in 1 ml MACS buffer and were 
analysed on the Vi-Ceii-XR Cell Viability Analyser in order to count the number of 
cells bound to the beads. 
5.1 0. Preliminary Patient Test 
Red blood cell (RBC) lysis buffer (140mM NH4CI, 17mM Tris, pH 7.65) was 
added to a patient blood sample to a total volume of 50ml and incubated at 37°C 
until the solution became clear, indicating complete lysis. The solution was 
centrifuged at 300g for 5 minutes at 4°C and the supernatant was discarded. The 
pellet was washed in RBC lysis buffer, centrifuged again, the supernatant was 
discarded and the pellet was resuspended in 3ml MACS buffer. This solution was 
split into 3 tubes and 11JI of 1/10 diluted beads was added, a different bead type 
for each tube. The tubes were incubated on a roller for 30 minutes at 4°C to allow 
binding and subsequently placed on a magnet to collect the beads. The beads 
were washed 5 times with MACS buffer, resuspended in 1 001JI of MACS buffer 
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and mounted onto microscope slides with a drop of Prolong Gold anti-fade 
reagent containing DAPI (Invitrogen) as described in 5.8. 
5.11. Control Blood- 30 Minute versus Overnight Incubation 
A control blood sample was incubated at 37°C with RBC lysis buffer until lysis 
was complete. The solution was centrifuged at 300g for 5 minutes at 4 °C to pellet 
the remaining cells and the supernatant was discarded. The pellet was washed in 
RBC lysis buffer, re-pelleted and the supernatant was discarded. The pellet was 
resuspended in 6 ml MAGS buffer and split into 6 eppendorf tubes. 11JI of 1/10 
diluted beads was added to each tube, with each bead type being added to two 
tubes. One set of tubes was incubated on a roller for 30 minutes at 4°C, while the 
second set of tubes was incubated on a roller at 4°C overnight. 
Tubes were subsequently placed on a magnet to collect the beads and washed 
five times with MAGS buffer. The beads were resuspended in 1 001JI MAGS 
buffer, pipetted onto coverslips on a magnet, the wash buffer was aspirated and 
the beads were mounted onto microscope slides. 
5.12. Trypan Blue Staining of Captured Cells 
RBC lysis of a patient blood sample was performed as described in 5.1 0. The 
solution was centrifuged at 300g for 5 minutes at 4°C and the supernatant was 
removed. The pellet was washed in RBC lysis buffer, centrifuged again and the 
supernatant was discarded once more. The pellet was resuspended in 1 ml 
MAGS buffer and 11-11 of 1/10 diluted MCAM beads was added. The sample was 
incubated on a roller at 4°C overnight to allow binding. The tube was placed on a 
magnet and the beads were washed 5 times with MAGS buffer. The beads were 
resuspended in 1 OOIJI of MAGS buffer, mixed with 0.1% trypan blue and mounted 
on a microscope slide with a drop of Prolong Gold anti-fade reagent containing 
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DAPI (Invitrogen), as described in 5.8. 
5.13. MACS versus Triton X-1 00 Wash 
A2058 and HEK293 cells were harvested with accutase and counted on the Vi-
Ceii-XR Cell Viability Analyser (Beckman Coulter). The volume of approximately 
106 cells was calculated for each cell type and added to an eppendorf tube. 11-11 of 
MCAM beads was added to each tube and the tubes were incubated on a roller 
for 30 minutes at 4°C to allow binding. Each tube was then split into two and 
placed on a magnet. One set of tubes containing A2058 and HEK293 cells were 
washed 5 times with MAGS buffer (2mM EDTA, 0.5% BSA in PBS, pH 7.2), while 
the other set of tubes were washed 5 times with 0.2% Triton X-100 in PBS. 
Samples were then mounted onto microscope slides with a drop of Prolong Gold 
anti-fade reagent containing DAPI (Invitrogen), as described in 5.8. 
5.14. Blood Spiking 
A2058 cells were harvested with EDTA media (2mM EDTA in DMEM media) and 
resuspended in 1Om I of DMEM media containing 10% FBS. 1 ml of cells was 
diluted 1/10 in a petri dish for spiking into blood. RBC lysis of control blood 
performed as described in 5.1 0. The cells were pelleted at 300g for 5 minutes at 
4°C and the supernatant was discarded. The pellet was resuspended in MAGS 
buffer and 0.5ml was analysed on the Vi-Ceii-XR Cell Viability Analyser 
(Beckman Coulter) to determine cell count and viability. The remainder of the 
resuspended blood cells were split equally into eppendorf tubes. The desired 
number of A2058 cells were pipetted up from the petri dish under a microscope 
using a micropipette and spiked into the eppendorf tubes containing control blood 
cells. 1, 10, 30, 50 and 100 cell spikes were performed and repeated four times. 
Once A2058 cells had been spiked into blood cells, 11JI of 1/10 diluted MCSP 
beads was added and tubes were incubated on a roller at 4°C overnight. 
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The tubes were placed on a magnet to collect the beads, the supernatant was 
removed and the beads were washed 5 times in MAGS buffer containing 0.2% 
Triton-X 100. The beads were resuspended in 1 001-JI MAGS buffer with 0.2% 
Triton-X 100 and mounted on microscope slides with a drop of Prolong Gold 
anti-fade reagent containing DAPI (Invitrogen), as described in 5.8. Cells were 
then counted by fluorescence microscopy with an epifluorescent Olympus BX51 
microscope equipped with an Olympus DP71 camera to determine the number of 
spiked cells retrieved following incubation with the beads. 
5.15. Non-Specific Binding in Fresh versus 4 Day Old Blood 
Two control blood samples were taken from a healthy volunteer and one was 
processed immediately while the other was refrigerated and processed after 4 
days. RBC lysis of samples was performed as described in 5.1 0. The remaining 
' cells were pelleted at 300g for 5 minutes at 4°C and the supernatant was 
discarded. The pellet was washed in RBC lysis buffer, re-centrifuged and the 
supernatant was again removed. The pellets were resuspended in 3.5ml MAGS 
buffer, 0.5ml was analysed on the Vi-Ceii-XR Cell Viability Analyser (Beckman 
Coulter) to determine cell count and viability and the remaining 3ml was split into 
3 tubes. 11-JI of 1/10 diluted beads was added to each tube, one bead type per 
tube, and the tubes were incubated on a roller at 4°C overnight. Tubes were 
placed on a magnet and washed 5 times with 0.2% Triton X-100 in MAGS buffer. 
The beads were resuspended in 1 001-JI of the wash buffer, mounted onto 
microscope slides with a drop of Prolong Gold anti-fade reagent containing DAPI 
(Invitrogen), as described in 5.8., and viewed by fluorescence microscopy with an 
Olympus BX51 microscope equipped with an Olympus DP71 camera. 
5.16. Isolation of Circulating Melanoma Cells from Patient Blood 
To isolate melanoma cells from patient blood samples, firstly RBC lysis was 
performed as described in 5.1 0. The solution was pelleted at 300g for 5 minutes 
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at 4°C and the supernatant was discarded. The pellet was washed in RBC lysis 
buffer and re-pelleted to remove any remaining unlysed red blood cells. The 
pellet was resuspended in 3.5ml of MACS buffer (2mM EDTA, 0.5% BSA in PBS, 
pH 7.2) and mixed thoroughly to remove any cell clumps and homogenise the 
solution. 0.5ml of this sample was analysed on the Vi-Ceii-XR Cell Viability 
Analyser (Beckman Coulter) to determine cell count and viability. The remaining 
3m I was split into 3 eppendorf tubes and 11-11 of 1/10 diluted beads were added, 
one bead type per tube. The blood cells and beads, suspended in 1 ml MACS 
buffer, were incubated overnight on a roller at 4 °C. 
Tubes were then placed on a magnet to collect the beads and any bead-bound 
cells and the supernatant, containing unbound cells, was removed. The beads 
were then washed five times with 5001JI of MACS buffer containing 0.2% Triton 
X-1 00 to remove any non-specifically bound cells. The beads were resuspended 
in 1 OO!JI MACS buffer containing 0.2% Triton-X 1 00 and were pi petted onto 
cbverslips on a magnet before being mounted onto microscope slides with a drop 
of Prolong Gold anti-fade reagent containing DAPI (Invitrogen), as described in 
5.8. Slides were left overnight to allow for full penetration of DAPI for optimal 
nuclear staining before being scanned by fluorescence microscopy using an 
Olympus BX51 microscope equipped with an Olympus DP71 camera in order to 
count the number of cells bound to each bead type. This protocol was performed: 
for 21 control blood samples and 33 patient blood samples. 
5.17. Statistical Analysis 
Results obtained after performing immunomagnetic bead capture on patient and 
control samples were analysed using Predictive Analytics Software (PASW) 
(IBM, Somers, New York, USA), in order to demonstrate any relationships 
between CTC numbers and disease stage. 
Firstly, the total numbers of captured cells in patient and control groups were 
compared using an independent samples t-test in order to illustrate the difference 
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between the mean numbers of captured cells in these two groups. A boxplot was 
generated in order to show the difference in the distribution of total captured cells 
between patient and control groups. 
The relationship between the total cell count and the total captured cells of 
patient samples was analysed using the Pearson product-moment correlation 
coefficient. This analysis was performed in order to demonstrate the relationship 
between these two continuous variables to show whether total cell count was a 
confounding variable and therefore influenced the number of cells captured by 
immunomagnetic isolation. 
The relationships between total captured cells, MCSP cells, MCAM cells, ABCB5 
cells and disease stage were determined using Spearman's rank order 
correlation coefficient for non-parametric data. This test is useful for 
demonstrating correlation using ordinal, or ranked, variables, such as disease 
stage. These analyses were performed to show any correlations between these 
variables in order to demonstrate whether disease stage is a predictor of 
circulating cell numbers and thus support or refute the hypothesis that the 
number of circulating melanoma cells in patient peripheral blood correlates with 
disease stage. Patients were also split into non-metastatic (consisting of stage· 0, 
I and II) and metastatic (consisting of stage Ill and IV) groups, in order to 
demonstrate the difference between the mean number of total captured cells in 
metastatic and non-metastatic patients using an independent samples t-test. 
Patient 29, who had a total of 232 captured cells, was an extreme outlier and for 
this reason, statistical -analyses were performed including and excluding this 
patient. It was found that the inclusion of this patient did not have a significant 
effect on the outcome and thus, all results are shown with this patient included. 
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6. Results 
In this study, an assay for the isolation of circulating melanoma cells from patient 
peripheral blood samples by immunomagnetic bead capture was developed. 
First, target markers were chosen based on current literature and demonstration 
of their expression in melanoma cells and tissue by immunofluorescence. 
Antibody-coupled immunomagnetic beads were then manufactured and tested 
on control and melanoma cell lines in order to optimise the bead capture 
protocol. Finally, this protocol was performed for 21 control and 33 patient blood 
samples and the results were analysed to determine any relationships between 
the number of captured cells and disease stage. 
6.1. Demonstration of Chosen Antigen Expression in Melanoma Cell Line 
by Immunofluorescence 
Immunohistochemistry was performed to demonstrate MCSP, MCAM and 
ABCBS expression in A2058 melanoma cells. Demonstration of expression of 
these markers in a metastatic melanoma cell line will provide evidence 
suggesting these markers will also be expressed in melanoma CTCs and will 
therefore be useful target markers for capturing CTCs from patient blood. Alexa 
Fluor 488 (A488), conjugated to anti-mouse lgG (for MCSP and MCAM 
antibodies) and anti-rabbit lgG (for ABCB5 antibody) were used as secondary 
antibodies to detect positive staining in the cells by fluorescence microscopy. 
HEK293 cells, as well as A2058 cells with secondary antibody only, were used 
as negative controls and therefore should be unstained in order to demonstrate 
that melanoma cells were stained specifically as a result of antibodies binding to 
target markers on their cell surface. 
Fig.6.1.A shows A2058 cells stained with MCSP antibody and anti-mouse lgG 
conjugated to A488. All cells were positively stained as a result of lgG-A488 
binding to the cell surface via anti-MCSP, confirming MCSP expression in all 
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A2058 melanoma cells. In contrast, no staining was observed in HEK293 cells 
(Fig.6.1.B) indicating MCSP is not expressed in these cells and further confirming 
the specificity of MCSP for A2058 melanoma cells. Therefore, MCSP is a useful 
antigen to target for immunomagnetic isolation of circulating melanoma cells. 
Fig.6.1.C shows A2058 cells stained with MCAM antibody and anti-mouse lgG 
conjugated to A488. Again all cells were strongly positively stained whereas 
HEK293 cells were MCAM negative (Fig.6.1.D). This indicates that the MCAM 
antibody also binds specifically to A2058 melanoma cells and suggests MCAM is 
also a useful antigen to target for capturing circulating melanoma cells from 
patient blood. These results show that all A2058 melanoma cells are MCSP and 
MCAM positive, however this is not the case in all melanoma cells. MCSP is 
constitutively expressed in the majority of melanomas across all disease stages 
(Yang et al., 2004) whereas MCAM expression is associated with an aggressive, 
' invasive phenotype and is linked with later stage disease (Mangahas et al., 
2004 ). For this reason it is not expected that all circulating cells will be both 
MCSP and MCAM positive although it should be the case that all MCAM positive 
cells are also MSCP positive. Accordingly, a greater number of MCSP positive 
circulating cells than MCAM positive circulating cells are expected to be 
observed. 
No non-specific staining was observed in the negative control where cells were 
stained only with A488 conjugated lgG without primary antibody (Fig.6.1.G). This 
confirms that the immunofluorescence observed in A2058 cells stained for either 
MCSP or MCAM was specific. 
Attempts to demonstrate ABCB5 expression in A2058 melanoma cells by 
immunofluorescence with ABCB5 antibody was unsuccessful (Fig.6.1.E). This 
negative result is presumably due to the lack of suitability of this specific ABCB5 
antibody for immunohistochemistry, an application for which it has not been 
tested (Rockland lmmunochemicals, 201 0). The alternative method of flow 
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cytometry was used to demonstrate ABCB5 expression in A2058 cells as 
reported below. 
Figure 6.1. Immunofluorescence of A2058 melanoma cell line with MCSP, MCAM and 
ABCB5 antibodies. HEK293 cells were used as a negative control for each antibody. 
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6.2. Demonstration of ABCB5 Expression in Melanoma Cell Line by Flow 
Cytometry 
ABCB5 expression in A2058 melanoma cells was unable to be demonstrated by 
immunofluorescence, as illustrated in Fig. 6.1.E. For this reason, flow cytometry 
was performed with ABCB5 primary antibody and A488 conjugated secondary 
antibody to determine the percentage of ABCB5 expressing A2058 cells. Again, 
HEK293 cells and A2058 cells with only secondary antibody were used as 
negative controls to demonstrate ABCB5 staining was specific due to ABCB5 
antibody binding to ABCB5 on the surface of A2058 cells. 
Fig.6.2.A shows the peak fluorescence emission of A2058 cells without antibody, 
which has been adjusted to sit entirely within the first decade of the graph in 
order to observe any increased fluorescence in samples containing A2058 cells 
bound to antibody. All graphs were gated by placing a boundary at the first 
decade to separate cells within the first decade (unstained cells) from those with 
increased fluorescence. This was performed to demonstrate the percentage of 
cells which had increased fluorescence, and were therefore considered positive, 
compared with those contained in the first decade of the graph. Analysis of 
results following gating of the graphs revealed that 0.44% of unstained A2058 
cells had increased fluorescence in Fluorescence Channel 1 (FL 1) and 0.35% of 
cells had increased fluorescence in Fluorescence Channel 2 (FL2) (Fig.6.2.A). 
Fig.6.2.B shows the fluorescence emission of A2058 cells bound to MCSP 
antibody, which was used as a positive control in this experiment. The MCSP 
antibody was conjugated to the fluorochrome PE which produces a peak 
emission at 575nm and should be seen in FL2. When A2058 cells were stained 
with MCSP antibody and analysed by flow cytometry, an increased fluorescence 
was observed in FL2 as the bulk of the cell population was visible outside of the 
first decade of the graph, demonstrating that the cells were bound to the MCSP 
antibody. Gating the graph to determine the proportion of cells outside the first 
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decade revealed that 99.56% of cells were MCSP positive shown by an increase 
in relative fluorescence. 
To identify the number of A2058 cells positive for ABCB5, cells were incubated 
with ABCB5 antibody and secondary antibody, conjugated to Alexa Fluor 488 
(A488) before being analysed by flow cytometry. A488 produces a peak emission 
at 519nm which should be observed in FL 1. As shown in Fig.6.2.C, there is a 
slight shift of the cell population in FL 1 which suggests a small number of A2058 
cells have increased fluorescence at 519nm and are therefore positive for 
ABCB5. Gating of this graph to demonstrate the proportion of cells with 
increased fluorescence revealed that 5.05% of these cells appeared outside of 
the first decade of the graph in FL 1, which shows that a small population of 
A2058 cells are ABCB5 positive. It was expected that only a small percentage of 
A2058 cells would be ABCB5 positive as this marker is only expressed on a 
subset of melanoma stem cells (Chen et al., 2005). 
A2058 cells with secondary anti-mouse lgG, conjugated to A488 alone, without 
primary antibody was used as a negative control (Fig.6.2.D.). Gating of FL 1 
following analysis by flow cytometry revealed that only 0.52% of cells had 
increased fluorescence when no primary antibody was present. This negative 
control confirms that ABCB5 is expressed in approximately 5% of A2058 cells 
(Fig.6.2.C) and highlights the fact that ABCB5 expression is limited to melanoma 
stem cell populations, or at least rare melanoma cells, as opposed to MCSP and 
MCAM expression which was observed in all cells of the A2058 melanoma cell 
line (Fig.6.1.A and Fig.6.1.C respectively). 
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Figure 6.2. Analysis of ABCB5 expression in A2058 melanoma cells by flow cytometry. The 
peak emission of A2058 cells alone was adjusted to sit within the first decade of the graph and 
graphs were then gated (shown as the horizontal line beginning at 1 0°) to separate cells with 
increased fluorescence from those within the first decade of the graph in order to reveal the 
percentage of cells with increased fluorescence in each sample. Cells appearing outside the first 
decade of the graph as a result of increased fluorescence were considered positive. 
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6.3. Demonstration of MCAM and MCSP Expression in Melanoma Tissue 
Sections by Immunofluorescence 
Paraffin-embedded melanoma tissue sections were stained with MCAM and 
MCSP antibodies to demonstrate expression of these markers in melanoma 
tumours by immunofluorescence. ABCB5 staining was not performed due to the 
inability to stain A2058 melanoma cells with ABCB5 antibody by 
immunofluorescence. Three sections each of in situ, invasive primary and 
metastatic melanoma were stained in order to demonstrate the relative 
expression of these markers in melanoma tissue of different disease stages. The 
idea of this was to illustrate marker expression relative to disease progression in 
order to demonstrate the suitability of MCSP and MCAM as antigens to target in 
the isolation of melanoma CTCs and to provide an idea of the number of MCSP 
and MCAM positive circulating cells expected relative to disease stage. Specific 
staining of tissue sections was confirmed by staining of paraffin-embedded 
A2058 cells as a positive control, as A2058 cells were shown to be MCAM and 
MCSP positive (Fig.6.1.), and staining of sections with secondary antibody only, 
with no primary antibody, as a negative control to observe background 
fluorescence and therefore confirm true staining. 
Fig.6.3.A and Fig.6.4.A show a section of in-situ melanoma of the superficial 
spreading type, which was excised from a patient's left arm. Within the lesion 
there were one or two small nests of invasive cells, although invasion was 
confined to the superficial epidermis, as described in the patient's histopathology 
report. Staining with MCAM antibody and Alexa Fluor 488 (A488), conjugated to 
anti-mouse lgG (Fig:6.3.A), revealed small clusters of strongly positive cells 
sparsely distributed within the lower epidermis. Staining with MCSP antibody and 
A488 (Fig.6.4.A) revealed small clusters of weakly stained cells as well as weakly 
stained individual cells scattered throughout the epidermis. 
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Fig.6.3.8 and Fig.6.4.8 show a different section of the same superficial spreading 
in-situ melanoma seen in Fig.6.3.A and Fig.6.4.A. Staining with MCAM antibody 
and A488 (Fig.6.3.8) revealed small clusters of strongly positive cells distributed 
throughout the epidermis. Staining with MCSP antibody and A488 (Fig.6.4.8) 
also showed small clusters of positively stained cells within the epidermis 
although staining was weaker. 
Fig.6.3.C and Fig.6.4.C show a section of superficial spreading in-situ melanoma 
that has developed within a dysplastic naevus which was excised from the right 
shoulder of a patient. Staining with MCAM antibody and A488 (Fig.6.3.C) 
revealed a very large area of MCAM expressing cells throughout a large portion 
of the epidermis of the section, which may indicate that many cells within this 
tumour have an aggressive phenotype although it was excised while in-situ. 
Smaller clusters of positive cells, as well as individual positive cells, were also 
seen spread throughout the epidermis. Staining with MCSP antibody and A488 
(Fig.6.4.C) similarly demonstrated small clusters of MCSP positive cells as well 
as positively stained individual cells distributed throughout the epidermis of this 
lesion. 
Fig.6.3.D and Fig.6.4.D show a section of invasive, ulcerated, nodular, 
melanoma excised from the back of a patient. The tumour is 4.77mm in depth 
from the stratum granulosum, or granular layer, of the epidermis and the patient 
was diagnosed histologically to be at clinical disease stage Ill at the time of 
excision of the primary tumour. Staining with MCAM antibody and A488 
(Fig.6.3.D) revealed small areas of positively stained cells spread throughout the 
epidermis and dermis. Staining with MCSP and A488 antibodies (Fig.6.4.D) 
similarly revealed a few individual cells positive for MCSP distributed throughout 
the epidermis and dermis. 
Fig.6.3.E and Fig.6.4.E show a section of invasive superficial spreading 
melanoma excised from a patient's brow. The tumour measures 1.03mm in depth 
from the stratum granulosum and the patient was diagnosed as having stage II 
45 
disease at the time of tumour excision. Staining with MCAM and A488 antibodies 
(Fig.6.3.E) revealed small clusters of positive cells along with individual positive 
cells scattered throughout the epidermis and dermis. Staining with MCSP and 
A488 antibodies (Fig.6.4.E) revealed small clusters of weakly stained cells 
predominantly within the dermis. 
Fig.6.3.F and Fig.6.4.F show a section of invasive superficial spreading 
melanoma excised from the left back of a patient. The tumour measured 1.74mm 
in depth from the stratum granulosum and the patient was diagnosed as having 
stage II disease at the time of primary tumour removal. Staining for MCAM and 
A488 (Fig.6.3.F) revealed medium to large areas of positively stained cells, along 
with small positive clusters of cells, distributed throughout the epidermis and 
dermis. Staining for MCSP and A488 (Fig.6.4.F) revealed small clusters of 
positive cells distributed along the lower epidermis. Staining of these cells was 
slightly stronger than previous MCSP staining although more patchy. 
Fig.6.3.G and Fig.6.4.G show a section of a melanoma metastasis excised from 
the skin above the right scapula of a patient. The epidermis in these sections 
appeared normal in structure whereas the dermis appeared highly disorganised. 
Staining with MCAM and A488 antibodies (Fig.6.3.G) revealed very little MCAM 
expression in the epidermis whereas the majority of cells of the dermis were 
MCAM positive. Staining for MCSP and A488 (Fig.6.4.G) revealed small clusters 
of MCSP positive cells and individual positively stained cells scattered throughout 
the dermis. 
Fig.6.3.H and Fig.6.4-.H show a section of a melanoma metastasis excised from 
the skin of a patient's right arm. Structure of the epidermis in these sections 
appeared normal whereas the dermis appeared more disorganised and 
unstructured. Staining for MCAM and A488 (Fig.6.3.H) demonstrated that the 
majority of cells of the dermis were MCAM positive while the cells of the 
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epidermis were negative. Staining for MCSP and A488 (Fig.6.4.H) showed small 
to medium areas of positively stained cells throughout the dermis. 
Fig.6.3.1 and Fig.6.4.1 show a section of a melanoma metastasis with a lymph 
node replaced by malignant melanoma cells. The tissue structure appeared 
highly disorganised with densely packed cells of varying morphology. Staining for 
MCAM and A488 (Fig.6.3.1) revealed that the entire section was positive for 
MCAM. Staining for MCSP and A488 (Fig.6.4.1) revealed medium to large areas 
of positive cells distributed throughout the tissue although staining was weak. 
Overall, there was an observed increase in the number of positively stained cells 
as disease severity increased as the majority of cells in metastatic tissue were 
positively stained compared with few positive cells in early stage tissue. This 
finding suggests disease progression may be associated with an increase in 
melanoma CTCs, especially since the number of MCAM positive cells, which are 
associated with aggressive, invasive behaviour, increased with disease severity. 
The demonstration of expression of these markers in all tissue sections from in 
situ to metastatic disease also supports the proposal that these markers are 
useful target antigens for the isolation of melanoma CTCs by immunomagnetic 
bead capture. 
It is important to note that the MCSP antibody used in this experiment produced 
inferior results to the MCAM antibody as there was more MCAM staining 
observed than MCSP staining and MCSP staining was significantly weaker. 
MCSP is generally noted in the literature to be expressed on the majority of 
melanoma cells (Yang et al., 2004); however this was not observed in this 
experiment. The less than optimal results obtained for MCSP staining are 
thought to be due to difficulties with this particular antibody when used for 
immunohistochemistry. Although results were improved by multiple experiments 
trialling different antibody concentrations and antigen retrieval methods, results 
were not as clear or consistent as those achieved using the MCAM antibody. 
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Optimisation of these results would require additional MCSP antibodies to be 
trial led. 
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Figure 6.3. Immunohistochemistry of paraffin embedded melanoma tissue sections, 
stained with MCAM antibody and secondary anti-mouse lgG conjugated to A488. Red 
circles in the 1 OOX magnified images illustrate the positively stained area shown at 
400X magnification. 
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Figure 6.4. Immunohistochemistry of paraffin embedded melanoma tissue sections, 
stained with MCSP antibody and secondary anti-mouse lgG conjugated to A488. Red 
circles in the 1 OOX magnified images illustrate the positively stained area shown at 
400X magnification. 
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6.4. Testing the ability of Antibody-Coupled lmmunomagnetic Beads to 
Bind Melanoma Cells 
A2058 cells were incubated with anti-
MCSP, anti-MCAM and anti-ABCB5 
coupled immunomagnetic beads in 
order to test their ability to bind A2058 
melanoma cells, which have 
previously been shown to express 
these markers by immunofluorescence 
and flow cytometry (Fig.6.1 and 
Fig.6.2. respectively). If the beads bind 
these cells successfully then they 
should also be able to bind circulating 
melanoma cells expressing these 
markers. The binding of A2058 cells to 
each bead type was observed by 
fluorescence microscopy. 
Fig.6.5.A shows anti-MCSP coupled 
immunomagnetic beads bound to 
A2058 cells. This image shows that 
anti-MCSP coupled beads (red) are 
successful at binding A2058 cells, 
which are MCSP positive, as indicated 
in Fig. 6.1.A. The ability of anti-MCSP 
coupled beads to bind A2058 cells 
implies that similar results should also 
be obtained when they are used to 
bind MCSP positive circulating 
melanoma cells from patient blood. Figure 6.5. Testing anti-MCSP, anti-MCAM and anti-
ABCB5 coupled immunomagnetic beads on A2058 
melanoma cells. 
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The result of this test also demonstrated that 11JI of anti-MCSP coupled beads 
was able to bind many thousand A2058 cells. 
Fig.6.5.B shows anti-MCAM coupled immunomagnetic beads bound to A2058 
cells. This image shows that anti-MCAM beads also bind A2058 cells 
successfully, which are MCAM positive (Fig. 6.1.C.), and should therefore be 
able to bind circulating MCAM positive cells from patient blood. The result of this 
test demonstrates 11JI of anti-MCAM beads is also capable of binding thousands 
of A2058 cells. 
Fig.6.5.C shows anti-ABCB5 coupled beads bound to A2058 cells. This result 
demonstrates that anti-ABCB5 beads were able to bind only a small percentage 
of A2058 cells. Similar results were observed with flow cytometry (Fig.6.2.C.), 
suggesting only a small sub-population of A2058 cells are ABCB5 positive which 
are likely to be stem or rare melanoma cells. This suggests that the anti-ABCB5 
beads bind ABCB5 positive cells specifically and should therefore be successful 
at isolating ABCB5 positive circulating melanoma stem cells from patient blood . 
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6.5. Testing the Binding Capacity of Antibody-Coupled immunomagnetic 
Beads by Cell Counting 
A2058 melanoma cells were incubated with anti-MCSP, anti-MCAM and anti-
ABCB5 beads and counted on the Vi-Ceii-XR Cell Viability Analyser (Beckman 
Coulter) in order to demonstrate the binding capacity of 11JI of each bead type, 
i.e. the amount of cells 11-11 of beads is capable of binding. HEK293 cells were 
used as a negative control to demonstrate the amount of non-specific binding 
resulting from incubation with each bead type. 
Table 6.1.demonstrates the binding capacity of 11-11 of anti-MCSP, anti-MCAM 
and anti-ABCB5 coupled immunomagnetic beads when incubated with 5x1 05 
A2058 and 5x1 05 HEK293 cells. The cell count was generated using the Vi-Ceii-
XR Cell Viability Analyser, which counts the number of cells in a representative 
portion of the sample to determine the approximate number of cells per ml of 
sample. 
The results show that 11-11 of each bead type is capable of binding many thousand 
A2058 cells, although the number of cells bound to anti-ABCB5 beads seems 
high compared to previous results. This test also demonstrated that all three 
bead types exhibited a high level of non-specific binding as each bead type 
bound approximately 50,000 HEK293 cells which are negative for MCSP, MCAM 
and ABCB5 (Fig. 6.1.). This high level of non-specific binding of the beads was 
possibly due to conjugated antibodies or the beads themselves attaching to the 
surface of cells other than through an antibody-antigen bond. This non-specific 
binding would need to be overcome before isolating circulating cells from patient 
blood to ensure captured cells have been bound specifically based on expression 
of a particular marker. 
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Table 6.1. The binding capacity of 11-11 anti-MCSP, anti-MCAM and anti-ABCB5 
coupled immunomagnetic beads as determined by the Vi-Ceii-XR Cell Viability 
Analyser (Beckman Coulter). 
Sample Cells 
A2058 + MCSP Beads 0.14x106 
A2058 + MCAM Beads 0.067 x106 
A2058 + ABCBS Beads 0.073 x106 
HEK293 + MCSP Beads 0.046 x106 
HEK293 + MCAM Beads 0.052 x106 
HEK293 + ABCBS Beads 0.058 x106 
6.6. Testing Antibody-Coupled lmmunomagnetic Beads on a Preliminary 
Patient Sample 
A patient blood sample was tested to assess the number of cells captured by 
each bead type. Based on the high binding capacity of 11-11 of beads 
demonstrated in Table 6.1., it was decided to use 11-11 of 1/10 diluted beads which 
should be sufficient to capture all circulating cells within any patient sample 
tested and save on the amount of beads used. Due to the large amount of 
unbound cells observed in the patient sample relative to bead-bound cells, and 
because the total number of cells (both bound and unbound) was far greater than 
expected, it was decided to count only bead-bound cells. Unbound cells were 
ignored as it was presumed they were non-specifically bound leukocytes which 
55 
had survived washing. This presumption was supported by the substantial 
amount of non-specific binding to HEK293 cells previously observed (Table 6.1.). 
The results also show a relatively high number of bead-bound cells captured by 
anti-MCAM beads compared to cells captured by anti-MCSP beads (Table 6.2). 
This was not expected as MSCP should be expressed in any cells which are 
MCAM positive as MCSP is expressed in the vast majority of melanoma cells 
(Yang et al., 2004). Due to this result, and given the relatively high number of 
anti-ABCB5 bead bound cells, it was thought that many cells had bound non-
specifically to the beads. This was further suggested by the large number of 
unbound cells in the sample which were thought to be non-specifically isolated 
leukocytes. 
Table 6.2. The number of bead-bound cells captured by immunomagnetic 
isolation in a preliminary patient blood sample. 
Sample Bead Bound Cells 
MCSP Beads 5 
MCAM Beads 126 
ABCB5 Beads 26 
6.7. Comparison of Non-Specific Binding of Beads between 30 Minute and 
Overnight Incubation 
In order to determine an optimal incubation time that ensures the maximum 
isolation of circulating melanoma cells from patient blood without increasing the 
amount of non-specific binding, an experiment was conducted using a control 
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blood sample to observe the difference in the number of cells bound non-
specifically by each bead type between a 30 minute and overnight incubation. 
Therefore, the idea of this experiment was to determine whether an increased 
incubation time increases the amount of non-specific binding of the beads. Again, 
only bead-bound cells were counted due to the large number of unbound cells 
observed in the samples, presumably due to non-specific binding. The resu lts 
showed that an overnight incubation did not increase the amount of non-specific 
binding (Table 6.3.), suggesting an overnight incubation could be used for patient 
samples. The number of bound cells in each sample was however greater than 
expected in a control blood sample further suggesting a problem with non-
specific binding of leukocytes to the beads. 
Table 6.3. Comparison of the number of bead-bound cells captured from control 
blood with immunomagnetic beads for 30 minute and overnight incubation. 
Bead Bound Cells 
Sample 
30mins Overnight 
MCSP Beads 10 2 
MCAM Beads 4 8 
ABCB5 Beads 5 2 
Total Cells 19 12 
6.8. Demonstration of Captured Cell Viability by Trypan Blue Staining 
In this experiment, a patient blood sample was incubated overnight with anti-
MCAM coupled immunomagnetic beads, washed with MAGS buffer (2mM EDTA, 
0.5% BSA in PBS, pH 7.2) and stained with 0.1% trypan blue solution in order to 
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determine whether cells captured by immunomagnetic beads were viable. Trypan 
blue does not stain viable cells as it is unable to pass through the intact cell 
membrane of a live cell. On the other hand, trypan blue does pass through the 
cell membrane of a dead cell and therefore selectively stains dead cells blue. 
Following washing of the beads and mixing bead-bound cells with trypan blue 
solution, the viability of captured cells was observed by microscopy. Fig.6.6. 
shows cells captured by anti-MCAM coupled beads are live as there is an 
absence of blue staining within the cells. It was observed that all captured cells 
were viable as all were unstained. 
Figure 6.6. Trypan blue stain of cells captured by anti-MCAM immunomagnetic beads from 
patient blood. The absence of blue cellular staining indicates captured cells are viable. 
6.9. Comparison of MACS Buffer and Triton X-1 00 Washing to reduce Non-
Specific Binding of Beads 
Previous results have demonstrated a relatively high level of non-specific binding 
by the immunomagnetic beads when either HEK293 control cells (Table 6.1.) or 
control blood samples (Table 6.3.) were utilised. In order to reduce non-specific 
binding, a more stringent washing buffer containing 0.2% Triton X-100 was 
tested. Previous results had shown that the highest level of non-specific binding 
was produced by anti-MCAM coupled beads (Table 6.2., other results not 
shown). In this experiment, anti-MCAM beads were incubated with both A2058 
and HEK293 cells. Following incubation, both samples were split into two; one 
washed with MACS buffer and the other with 0.2% Triton X-100 in PBS in order 
to compare the amount of non-specific binding between the samples. Following 
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washing, the beads were mounted onto microscope slides and viewed by 
microscopy in order to determine whether washing with 0.2% Triton X-100 in 
PBS reduced the amount of non-specific binding of anti-MCAM beads to HEK293 
cells. 
Fig.6.7.A demonstrates the binding of A2058 cells by anti-MCAM coupled beads 
following washing with MACS buffer. Fig.6.7.B shows A2058 cells are still bound 
to the beads following washing with 0.2% Triton X-100, however the cells have 
clumped together making it difficult to distinguish individual cells and therefore 
count them. However, based on the number and size of the clumps, as seen in 
Fig.6.7.B, it was estimated that the number of cells in the sample was similar to 
the number of cells observed following washing with MACS buffer (Fig.6.7.A). 
This demonstrated that the Triton X-1 00 has not caused specifically bound 
A2058 cells to be removed from the beads during washing. Due to the fact that 
5x1 05 cells were used in protocol optimisation experiments, it was thought that 
clumping would not be an issue when quantifying cells from patient blood 
following Triton X-100 washing, as far lower numbers of captured cells were 
expected. 
Fig.6.7.C shows a large number of HEK293 cells non-specifically bound to anti-
MCAM beads which were not removed by washing with MACS buffer. On the 
other hand, there were no HEK293 cells observed following washing with 0.2% 
Triton X-1 00 in PBS (Fig.6.7.D) demonstrating the effectiveness of Triton X-1 00 
at removing non-specifically bound HEK293 cells from anti-MCAM beads. As a 
result of this experiment, MACS buffer containing 0.2% Triton X-1 00 was 
produced to be used for washing patient and control samples following overnight 
incubation with the beads in the final optimised protocol. 
Due to the low number of captured cells observed in further testing with 0.2% 
Triton X-100 washing, with very few unbound cells seen, it was decided to count 
all cells in the sample rather than bead-bound cells only. It was thought that the 
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very few unbound cells remaining in the sample would initially have been bead-
bound in order to be isolated from the sample and survive stringent washing with 
0.2% Triton X-100 in MACS buffer. It may have been the case in the few cells 
that were not bead-bound during viewing by microscopy that the bead-cell bond 
was broken following mounting the cells onto a microscope slide and leaving 
overnight for optimal nuclear staining with DAPI. This was suggested as unbound 
cells were usually observed extremely closely to at least one bead . 
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Figure 6.7. Comparison of non-specific binding of HEK293 cells by anti-MCAM coupled beads between 
MACS buffer and 0.2% Triton X-100/PBS washing. 6.6.0 was photographed by light microscopy rather than 
fluorescence microscopy for a clearer image of the unbound beads as no cells were present. 
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6.1 0. Demonstration of Assay Sensitivity and Specificity by Spiking 
Melanoma Cells into Control Blood 
In this experiment, increasing numbers of A2058 cells were spiked into control 
blood samples and incubated with anti-MCSP coupled beads overnight. 
Following washing and mounting the beads onto microscope slides, the number 
of cells in each sample was counted by microscopy in order to determine the 
sensitivity and specificity of the bead capture assay. The purpose of this was to 
determine the proportion of spiked cells that could be captured by the beads 
which may be comparable to the percentage of CTCs captured from a patient 
blood sample. Due to the variability in the number of cells retrieved with each 
spike, the experiment was replicated a number of times in order to determine an 
average number of cells retrieved for each number of cells spiked . 
Spiking with 0 cells demonstrated that there is a small amount of non-specific 
binding in the assay (Table 6.4); although it has been significantly reduced since 
Triton X-1 00 washing has been introduced. Due to the presence of some non-
specific background binding it cannot be determined whether a single A2058 cell 
was retrieved in the single cell spikes. In actuality, a decrease in the average 
number of cells retrieved in a single cell spike compared with a 0 cell spike is 
seen, although this is not significant. 
The mean values show that as the number of cells spiked increases, so too does 
the number of cells retrieved (Table 6.4.). However, it cannot be said from this 
experiment exactly how many A2058 cells were retrieved relative to non-
specifically bound cells. Nonetheless, assuming background bind ing remains 
constant throughout the samples, there is an apparent increase in the number of 
A2058 cells retrieved as the number of A2058 cells spiked is augmented. 
Although the number of cells retrieved increases with an increase in spiked cells, 
it can also be seen that as the number of cells spiked increases, the number of 
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cells retrieved becomes more variable. The explanation for this is that an 
increase in cell clumping associated with an increased number of spiked cells 
was observed. Many of these clumps appeared as a fluorescent blue smear 
where individual cells could not be distinguished and therefore could not be 
counted. The result of this was that frequently there were more cells retrieved by 
the beads than could be recorded as the exact number of cells could not be 
determined. 
Table 6.4. The number of cells retrieved after spiking control blood with an increasing 
number of A2058 cells and incubating with anti-MCSP coupled immunomagnetic beads. 
Approximate Cells Captured 
Number of 
Cells 
Spiked Spike 1 Spike 2 Spike 3 Spike 4 Mean 
0 4 3 5 5 4.25 
1 3 4 6 2 3.75 
10 9 14 10 6 9.75 
30 13 8 21 23 16.25 
50 42 31 29 40 35.5 
100 11.7 61 19 46 60.75 
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Figure 6.8. A graphical representation of the mean number of cells captured after spiking 
control blood with an increasing number of A2058 cells and incubating with anti-MCSP 
coupled immunomagnetic beads. 
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6.11. Comparison of Non-Specific Binding in Fresh and Four-Day-Old 
Control Blood 
The majority of patient blood samples included in this study were not fresh, 
instead averaging 3 days old. For this reason, an experiment was performed with 
control blood in order to determine whether increased age of the sample resulted 
in increased non-specific binding. In this experiment, two blood samples were 
taken from the same volunteer to be processed at different times. The first 
sample was processed within hours of it being taken while the second sample 
was processed after being refrigerated for 4 days. The results in Table 6.5. 
demonstrate that ageing the blood sample did not result in increased non-specific 
binding which suggests results obtained from older patient samples are as valid 
as those obtained from fresh samples. 
Table 6.5. Comparison of the number of non-specifically bound cells in fresh 
and 4 day old control blood. 
Cells 
Sample 
Fresh Blood 4 Day Old Blood 
MCSP Beads 0 1 
MCAM Beads 4 1 
ABCB5 Beads 0 0 
Total Cells 4 2 
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6.12. Results of lmmunomagnetic Bead Capture in Control Samples 
Table 6.6. shows the number of cells captured from control blood samples 
following immunomagnetic cell sorting with anti-MCSP, anti-MCAM and anti-
ABCB5 coupled beads. All samples were processed within hours of being taken 
and analysis with the Vi-Ceii-XR Cell Viability Analyser (Beckman Coulter) 
demonstrated that cell counts were relatively high and reasonably consistent. 
Furthermore, all samples had a high viability. 
Very few cells were captured in most samples demonstrating that the amount of 
non-specific binding seen in the assay is low; however some samples produced 
a relatively large number of captured cells as a result of cell clumping. Cell 
clumping was seen predominantly in samples 2, 13, 14 and 20 and explains the 
larger number of cells captured from these samples. This cell clumping did not 
appear to be related to total cell count, as demonstrated in Table 6.6. Also, there 
did not appear to be an association between clumping and a particular bead 
type. The reason for cell clumping in some samples was unclear. It may have 
resulted from washing with Triton X-1 00, as this caused A2058 cells to clump 
(Fig. 6.7.8.), or it may have been the case that some blood samples had a 
tendency to clump more than others as a result of the composition of cells within 
the sample which may have been altered, for example in response to injury or 
infection. The reason for cell clumps being captured by the magnetic beads was 
also unclear. This could have been due to beads becoming lodged in cell clumps 
during incubation or a single bead bound cell clumping with other unbound cells. 
Overall however, there was a significant difference observed between the 
number of cells captured in control samples versus patient samples, as 
described in 6.14.1. 
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Table 6.6. Results of the immunomagnetic bead capture protocol performed for 21 
control blood samples showing the total number of cells captured from each sample as 
well as the number of cells captured by each bead type. 
Sample Age of Total Cell Viability MCSP MCAM ABCBS Total 
Sample Count 
(x106/ml) 
(%) Cells Cells Cells Cells 
1 <1 day 4.86 98.9 1 0 0 1 
2 <1 day 3.83 99.2 0 0 8 8 
3 <1 day 6.51 99.0 0 0 0 0 
4 <1 day 2.27 98.8 0 1 1 2 
5 <1 day 4.71 99.0 0 1 0 1 
6 <1 day 6.21 98.9 0 0 1 1 
7 <1 day 3.68 97.9 0 0 0 0 
8 <1 day 3.27 98.2 1 0 0 1 
9 <1 day 4.50 97.8 0 1 0 1 
10 <1 day 4.47 99.1 1 0 0 1 
11 <1 day 2.27 99.2 0 2 0 2 
12 <1 day 3.09 98.7 3 0 1 4 
13 <1 day 4.30 97.7 12 3 1 16 
14 <1 day 3.11 98.7 0 0 10 10 
15 <1 day 5.04 98.4 0 0 1 1 
16 <1 day 2.51 99.1 0 0 1 1 
17 <1 day 3.92 96.4 1 2 0 3 
18 <1 day 2.83 97.4 1 1 0 2 
19 <1 day 2.92 98.5 1 0 1 2 
20 <1 day 2.26 94.7 14 3 0 17 
21 <1 day 4.29 98.0 3 0 1 4 
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6.13. Results of lmmunomagnetic Bead Capture in Patient Samples 
Table 6.7. shows the number of cells captured from patient samples following 
incubation with anti-MCSP, anti-MCAM and anti-ABCB5 immunomagnetic beads. 
Total cell counts in these samples, as determined by the Vi-Ceii-XR Cell Viability 
Analyser (Beckman Coulter), were more variable than those of control patients. 
This was possibly due to increased age range of the samples, compared with 
control samples, which were all processed within hours of collection, or an 
increased number of leukocytes in some patient samples as a result of a 
heightened immune response to their disease. Although the majority of patient 
samples were not fresh, ranging from 0 to 9 days old, all samples had a high 
viability, as determined by the Vi-Ceii-XR Cell Viability Analyser, suggesting the 
majority, if not all, melanoma CTCs within the sample were viable. Patient 
samples included in this study, presented in table 6.7, have been arranged in 
order of stage (0-IV) and available clinical information (date of diagnosis of 
current primary tumour and information regarding disease recurrence) has been 
included in the table for comparison with the number of captured cells. 
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Table 6.7. lmmunomagnetic bead capture results for 33 patient blood samples showing the number of cells captured by each 
bead type and available clinical data. 
Date of Diagnosis 
Sample Age of Total Cell Viability MCSP MCAM ABCB5 Total Disease of Current Primary Melanoma Recurrence Treatment (other 
Sample Count (%) Cells Cells Cells Cells Stage Tumour than primary 
(x10"6/ml) (month/year) removal) 
1 4 days 1.11 97.1 9 2 3 14 0 01/2009 None None 
2 4 days 0.58 95.8 4 0 3 7 0 02/2008 None None 
3 3 days 1.24 97.2 7 3 2 12 0 10/1999 None None 
4 4 days 0.34 95.7 0 1 0 1 0 05/1996 None None 
5 4 days 0.90 97.7 3 2 1 6 0 10/2004 2 primaries diagnosed around None 
same time 
6 4 days 1.49 97.3 55 4 5 64 0 08/2008 2 primaries diagnosed around None 
same time 
7 1 day 1.84 98.4 13 3 5 21 1 05/2009 First primary removed 09/2008 None 
8 1 day 1.12 91.4 21 1 14 36 1 07/2010 Recurrent disease- first primary None 
removed 10/1999,2 in-situ 
tumours removed 07/2010 
9 1 day 1.89 97.1 15 0 2 17 1 08/2010 Recurrent disease- first primary None 
removed 1 0/2006 
10 4 days 0.85 96.3 35 3 0 38 1 07/2010 None None 
11 3 days 0.83 96.5 3 0 2 5 1 10/1994 None None 
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Sample Age of Total Cell Viability MCSP MCAM ABCBS Total Disease Date of Diagnosis Melanoma Recurrence Treatment (other 
Sample Count (%) Cells Cells Cells Cells Stage of Current Primary than primary 
(x10A6fml) Tumour removal) 
(month/year) 
12 4 days 1.20 97.8 4 0 0 4 1 09/2010 2 primaries diagnosed around None 
same time 
13 2 days 2.07 98.3 14 0 1 15 1 07/2010 None None 
14 3 days 1.13 96.1 3 1 1 5 1 12/1997 None None 
15 7 days 1.64 96.1 20 3 7 30 1 05/2009 First primary removed 08/2008 None 
16 6 days 0.78 93.9 0 0 0 0 1 08/2009 None None 
17 <1 day 2.51 98.0 2 1 0 3 2 06/2006 None None 
18 3 days 2.95 70.7 10 1 5 16 2 02/2008 Recurrent primary tumour. None 
Diagnosed with invasive and in-
situ tumours at same time. 
19 4 days 0.73 96.7 8 1 0 9 2 02/2008 None None 
20 3 days 1.39 92.0 3 0 0 3 2 01/2004 Initial invasive primary removed, None 
second in-situ tumour diagnosed 
months later. 
21 9 days 0.77 94.0 26 3 9 38 2 02/2005 None None 
22 <1day 5.82 98.1 8 7 1 16 2 03/2010 None None 
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Sample Age of Total Cell Viability MCSP MCAM ABCB5 Total Disease Date of Diagnosis Melanoma Recurrence Treatment (other 
Sample Count (%) Cells Cells Cells Cells Stage of Current Primary than primary 
(x10A6fml) Tumour removal) 
(month/year) 
23 1 day 2.28 96.8 1 0 0 1 2 05/2009 Recurrent primary tumour None 
24 2 days 2.42 95.3 6 3 1 10 2 2005 None None 
25 6 days 2.63 97.3 26 3 6 35 3 07/2007 Nodal metastasis 02/08. None 
03/2009 new primary 
26 4 days 1.26 93.2 4 4 2 10 3 04/2005 None None 
27 <1 day 10.44 98.8 43 7 17 67 3 2010 In-situ melanoma removed in Radiotherapy 
1996. Metastatic melanoma 
diagnosed 04/2010 
28 <1 day 5.36 99.1 2 7 2 11 4 11/2002 9 secondary tumours removed Radiotherapy and 
11/2009 immunotherapy 
29 2 days 1.73 95.3 148 12 72 232 4 N/A Stage IV diagnosis 12/2003. 9 Vaccine 
secondary tumours removed (radiotherapy in 
between 12/2003 and 09/2008 2005) 
30 4 days 1.54 95.1 4 3 0 7 4 08/2009 Groin metastasis removed None 
09/2009 
2010- femoral lymph node and BRAF trial 
31 2 days 0.88 95.3 16 9 9 34 4 08/1996 multiple vertebral metastases 
removed 
02/2006 lung metastasis 
32 2 days 8.30 98.3 6 2 2 10 4 11/2002 removed, 02/2008 two None 
subcutaneous metastases in 
abdominal wall removed. 
33 1 day 2.93 98.7 10 13 7 30 4 2005 Multiple metastases removed, Immunotherapy 
most recent 06/2010 
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Figure 6.9. Scatterplot illustrating the total number of cells captu red in 21 control and 32 
patient samples. Patient 29 was not plotted, due to being an extreme outlier, in order to 
observe the difference in cell numbers in the remaining samples more clearly. 
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Figure 6.1 0. A graphical representation of the mean number of MCSP, MCAM, ABCBS and 
total captured cells for controls and patients relative to disease stage. 
Toni Cells 
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6.14. Statistical Analysis 
6.14.1. Total Captured Cells- Controls versus Patients 
An independent samples t-test was conducted to compare the total number of 
cells captured from patient and control groups. There was a significant difference 
in the number of cells captured from patient samples (mean=24.45, standard 
deviation=40.92) and control samples (mean=3.71, standard deviation=4.92), 
where t(33.44 )=2.88 and p=0.01. Fig. 6.11. shows a boxplot comparison of the 
total number of captured cells between patients and controls demonstrating the 
significant difference in distribution between the two groups. 
Comparison of the Distribution of Total Captured Cells between Control and Patient Samples 
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Figure 6.11. Boxplot comparing the distribution of the total number of cells captured in 21 control 
and 33 patient blood samples. Outliers are represented by circles and extreme outliers are 
represented by stars. Patient 29 was an extreme outlier with 232 cells although their score is not 
visible as a result of the limited y-axis scale. 
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6.14.2. The Relationship between Total Cell Count and Total Captured Cells 
It was thought that the total number of cells in any given patient sample may 
have an influence on the total number of cells captured from the sample as there 
is a degree of non-specific binding, which may be proportional to the number of 
cells in the sample. The relationship between the total cell count of the patient 
samples (as determined by analysis with the Vi-Ceii-XR Cell Viability Analyser) 
and the total number of captured cells was investigated using Pearson product-
moment correlation coefficient. There was an insignificant, extremely weak 
positive correlation between these variables (r=0.096, n=33, p=0.59) (Fig. 6.12. ), 
demonstrating that there is no relationship between the total number of cells in a 
sample and the number of cells captured from the sample by immunomagnetic 
isolation. This eliminates total cell count as a confounding factor. 
The Relationship between Total Cell Count and Total Captured Cells 
~Linear = D.DDQ 
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Total Cell Count (x10A6fml) 
Figure 6.12. Scatterplot of Total Cell Count vs Total Captured Cells for all 33 patient samples included 
in this study. The fit line has been added to the graph to demonstrate the extremely weak positive 
relationship between the two variables (r=0.096) which was insignificant (p=0.59). 
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6.14.3. Total Captured Cells versus Disease Stage 
The relationship between total captured cells and disease stage in patient 
samples was investigated using Spearman's rank order correlation coefficient. 
There was an insignificant, weak positive correlation between these variables 
(r=0.205, n=33, p=0.25) (Fig. 6.13. ), demonstrating that there is no true 
relationship between the total number of captured cells and disease stage within 
the sample population. A partial correlation between these variables was also 
performed controlling for total cell count, which had no effect on the outcome (not 
reported). This supports the results illustrated in Fig. 6.12., suggesting total cell 
count has no confounding effect on the total number of captured cells. 
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Figure 6.13. Scatterplot of total captured cells vs disease stage for all 33 patient 
samples included in this study. 
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Patient samples were also divided into two groups, metastatic and non-
metastatic, in order to analyse the difference in the mean number of total 
captured cells between these two groups by an independent samples t-test. 
Group 1 was made up of all non-metastatic patient samples (stages 0, I and II, 
n=24) while group 2 was made up of all metastatic patient samples (stages Ill 
and IV, n=9). The results showed there was a difference in the number of cells 
captured from metastatic patient samples (mean=48.44, standard 
deviation=71.45) and non-metastatic patient samples (mean=15.46, standard 
deviation=15.61 ), where t(8.288)=1.373. However, this difference was 
insignificant (p=0.21) due to the low sample sizes of the groups, especially the 
metastatic sample (n=9), and the inclusion of patient 29, an extreme outlier. Fig. 
6.14. shows a boxplot comparison of the total number of captured cells between 
metastatic and non-metastatic patients demonstrating the difference in 
distribution of total captured cell numbers between the two groups. 
Comparison of the Distribution of Total Captured Cells between Metastatic and Non-
Metastatic Patient Samples 
* 
2 
Non-Metastatic vs Metastatic Disease 
Figure 6.14. Boxplot comparing the distribution of the total number of cells captured in non-metastatic 
(group 1) and metastatic (group 2) patient samples. Extreme outliers are represented by stars although, 
again, patient 29 is not visible on the graph as a result of the limited y-axis scale. 
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6.14.4. MCSP Captured Cells versus Disease Stage 
The relationship between the number of cells captured with MCSP beads and 
disease stage in patient samples was investigated using Spearman's rank order 
correlation coefficient. There was an insignificant, weak positive correlation 
between these variables (r=0.116, n=33, p=0.521 ), demonstrating that there is no 
true relationship between the number of cells captured with MCSP beads and 
disease stage within the sample population (Fig.6.15.). 
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Figure 6.15. Scatterplot of captured MCSP cells versus disease stage for all 33 
patient samples included in this study. 
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6.14.5. MCAM Captured Cells versus Disease Stage 
The relationship between the number of cells captured with MCAM beads and 
disease stage in patient samples was investigated using Spearman's rank order 
correlation coefficient. There was a significant, medium positive correlation 
between these variables (r=0.486, n=33, p=0.004 ), demonstrating that there is a 
significant relationship between the number of cells captured with MCAM beads 
and disease stage (Fig. 6.16.). 
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Figure 6.16. Scatterplot of captured MCAM cells versus disease stage for all 33 
patient samples included in this study. 
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6.14.6. ABCB5 Captured Cells versus Disease Stage 
The relationship between the number of cells captured with ABCBS beads and 
disease stage in patient samples was investigated using Spearman's rank order 
correlation coefficient. There was an insignificant, weak positive correlation 
between these variables (r=0.190, n=33, p=0.289), demonstrating that there is no 
real relationship between the number of cells captured with ABCB5 beads and 
disease stage within the sample population (Fig. 6.17.). 
ABCBS Cells vs Disease Stage 
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Figure 6.1 7. Scatterplot of captured ABCB5 cells versus disease stage for all 33 patient 
samples included in this study. 
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7. Discussion 
The aim of this study was to quantify CTCs in peripheral blood samples from 
Cutaneous Malignant Melanoma patients in order to determine the 
relationship between the number of CTCs and clinical disease stage. 
lmmunomagnetic beads coupled with MCSP, MCAM and ABCBS antibodies 
were used to target three different melanoma cell surface antigens for optimal 
isolation of melanoma CTCs for subsequent quantification. The use of these 
three antibodies also demonstrated differences in circulating cell phenotype 
relative to disease stage as a result of expression of different target markers. 
Results of this study contribute to the development of a prognostic blood test 
that will aid in improving disease management and staging. In addition, 
quantification of circulating melanoma cells may prove useful in measuring 
treatment efficacy and identifying early stage patients requiring treatment. 
7.1. Total Captured Cells 
The total number of captured cells for each patient blood sample was defined 
as the sum of the number of cells captured with each bead type. This may not 
be a true representation of the total number of CTCs within whole blood 
samples as antibody-coupled beads would have only captured CTCs 
expressing the target antigen and therefore would not have captured other 
CTCs negative for that particular marker. It is also the case that cell counts for 
each marker may overlap as cells captured with anti-MCAM beads may also 
be MCSP positive and vice versa. For these reasons, total captured cell 
numbers are approximate values used to give some idea of CTC quantity. In 
order to produce a more accurate representation of total CTC numbers in 
future experiments, ·all bead types should be added to blood samples in 
combination. 
7 .2. Controls versus Patients 
There was a small amount of non-specific binding observed in control 
samples in this study; however, quantification of captured cells demonstrated 
that there was a statistically significant difference in the total number of cells 
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isolated from control and patient samples. If it is assumed that the amount of 
non-specific binding remains relatively constant in all blood samples, this 
demonstrates that the cell capture assay employed in this study was 
successful at binding circulating melanoma cells. Boxplot analysis of the 
distribution of total captured cells between control and patient groups also 
illustrated that the number of cells captured in patients was both larger and 
more variable than in control samples, which exhibited consistently low levels 
of non-specific binding (Fig. 6.11.). Given that the number of cells captured 
from patient samples was significantly higher than the number of cells 
captured from control samples, it is clear that CTCs were successfully isolated 
from patient samples. 
Other CTC isolation studies have also demonstrated low level non-specific 
background binding. For example, a study by Stott et al. (201 0) isolated CTCs 
from metastatic prostate cancer patients and stained captured cells with 
Prostate Specific Antigen (PSA), a highly specific prostate cell marker, and 
CD45, a leukocyte marker, in order to determine which cells were specifically 
bound CTCs versus non-specifically bound leukocytes. It was found that there 
was a degree of non-specific background binding to leukocytes in control 
samples, ranging from 0 to 8 cells (mean=3) (Stott et al., 2010). This was 
similar to the amount of non-specific binding observed in this study, where the 
number of cells captured in control samples ranged from 0 to 1 T (mean=3. 71 ). 
7 .3. Captured Cells versus Disease Stage 
Melanoma is an extremely heterogeneous disease and therefore CTCs are 
likely to have a variety of different phenotypes. For this reason a number of 
antigens were targeted in order to capture as many CTCs as possible from 
patient blood samples. Interestingly, there was only a moderate increase in 
the total number of captured cells relative to disease stage. Overall, it was 
observed that the number of CTCs isolated with anti-MCSP beads was 
greater than those isolated with anti-MCAM or anti-ABCBS beads regardless 
of disease stage, although similar numbers of MCSP positive cells were 
captured across all disease stages. In contrast, although the numbers of 
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captured MCAM positive CTCs were small, they significantly correlated with a 
more metastatic phenotype and therefore provided insight into the difference 
in CTC phenotype relative to disease stage. 
7.3.1. MCAM Cells versus Disease Stage 
Analysis of the correlation between the number of cells captured with anti-
' 
MCAM coupled beads and disease stage revealed a significant relationship 
between these variables (r=0.486, p=0.004) when assessed by Spearman's 
rank order correlation coefficient. This result indicates that as disease stage 
increases so too does the quantity of MCAM positive cells, although the 
amount of MCAM cells in all samples was relatively low compared with the 
number of MCSP cells. This is the first study to demonstrate a correlation 
between melanoma CTC phenotype and disease stage. This finding is 
however supported by current literature which details that MCAM expression 
in melanoma primary tumours increases with disease severity and is 
associated with aggressive and invasive tumour behavior (Mangahas et al., 
2004; Medic & Ziman, 201 0). Due to the aggressive and invasive phenotype 
of MCAM positive cells, it may be the case that these cells have increased 
tumour-forming capability. Circulating MCAM positive cells may therefore play 
a significant role in the extravasation of CTCs and subsequent invasion· of 
tissue sites around the body to form of metastases. The fact that the patients 
with the three highest quantities of captured MCAM positive cells (patients 33, 
29 and 31) are all stage IV patients and have all had multiple metastases 
supports this idea. 
7.3.2. MCSP Cells versus Disease Stage 
Interestingly, in contrast to results obtained for MCAM positive CTCs, analysis 
of the correlation between MCSP positive captured cells and disease stage 
demonstrated a weak positive relationship when assessed by Spearman's 
rank order correlation coefficient (r=0.116), however this was not statistically 
significant (p=0.52). MCSP is constitutively expressed in the majority of 
melanomas and is not related to disease progression (Yang et al., 2004); 
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however an increase in the number of MCSP positive CTCs was expected in 
metastatic patients compared with non-metastatic patients. In previous 
studies using anti-MCSP coupled immunomagnetic beads to isolate CTCs 
from melanoma patient blood samples, a correlation between CTC positivity, 
where a sample was positive if CTCs were isolated, and disease stage has 
been shown (Ulmer et al., 2004). Although MCSP positive CTCs were 
quantified in this study, the relationship between CTC quantity and disease 
stage was not determined as CTCs were only detected in 26% of samples 
tested. 
Increased numbers of CTCs are expected to be found in later stages of 
disease when cells of the primary tumour are more invasive or metastatic and 
are therefore able to escape the primary tumour and enter circulation. 
However, the results presented here suggest that in fact this may not be the 
case. In support of this finding, several reports indicate that a large number of 
cells are simply sloughed off the tumour regardless of stage (Bockhorn et al., 
2007). However, a stronger relationship between MCSP positive cells and 
disease stage may be shown with an increased sample size. 
7.3.3. ABCB5 Cells versus Disease Stage 
Similarly, statistical analysis using Spearman's rank order correlation 
coefficient showed a weak positive correlation between cells captured with 
ABCBS beads and disease stage (r=0.190), however this was not statistically 
significant (p=0.29). Like captured MCAM cells, the number of captured 
ABCBS cells was low compared with MCSP cells, often comparable to the 
amount of background binding observed in control samples. This is the first 
study to date detailing numbers of circulating melanoma stem cells in patient 
peripheral blood. The number of melanoma stem cells in circulation relative to 
non-stem circulating cells appears low although similar to expected values 
based on demonstration of ABCBS expression in the A2058 melanoma cell 
line, which suggested ABCBS was associated with rare melanoma cells (6.2.). 
An interesting point to note is that the patients with the three highest numbers 
of ABCBS positive cells (patients 8, 27 and 29), although all of different 
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disease stages, have all had the disease for many years; patient 8 was 
diagnosed in 1999, patient 27 in 1996 and patient 29 was diagnosed with 
stage IV disease in 2003. Furthermore, all three of these patients have 
recurrent disease. It may be the case that the large number of captured 
ABCBS cells in these patients is related to disease recurrence, as the 
proposed role of ABCBS positive melanoma stem cells is in tumour 
maintenance and renewal (Boiko et al., 2010; Sekulic et al., 2008). 
7.3.4. Total Captured Cells versus Disease Stage 
It is interesting to note the number of captured cells in patients with early 
stage, non-metastatic disease. This is an important finding demonstrating that 
CTCs are indeed present at early stages and may account for the significant 
number of patients with early stage disease who suffer recurrence, sometimes 
years after removal of the primary tumour (Jacket al., 2006; Koyanagi et al., 
2005a; Weight et al., 2006). 
Analysis of the correlation between total captured cells in patient samples and 
disease stage showed that there was no significant relationship. There was a 
weak positive correlation between these variables (r=0.205) and there was a 
differe-nce in the mean number of total captured cells between non-metastatic 
(stage 0, I and II) and metastatic (stage Ill and IV) patients (Fig. 6.1 0.). 
However, these findings were not statistically significant (p=0.25 and p=0.21 
respectively), possibly due to the small sample size. If more patient samples 
were included in the study, especially metastatic patient samples, these 
relationships may have approached significance as it was expected to see a 
significant increase [n the number of CTCs at least between non-metastatic 
and metastatic patients, if not across all disease stages. Again, however, it 
may be the case that cells are sloughed from the primary tumour and enter 
circulation regardless of an invasive phenotype (Bockhorn et al., 2007), 
resulting in similar numbers of CTCs across all disease stages. If this is the 
case then it may be the phenotype of CTCs that significantly differs relative to 
disease stage rather than the number of cells, as suggested by the significant 
increase in MCAM positive cells relative to disease stage as reported in 7.2.1. 
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7.4. Numbers of Captured Cells 
It has been suggested that CTCs circulate in patient blood at an approximate 
concentration of 1 in 106 to 107 blood cells (Krivacic et al., 2004). In the 
patient samples used in the study, the mean total cell count was 2.21 x1 06/ml 
in a 3.5ml sample, which equates to 7.74x106 cells, although this was post red 
blood cell lysis. The mean number of cells captured from these patient 
samples, containing 7. 7 4x1 06 total cells on average, was 24.45. When taking 
into account the presence of non-specific background binding and the fact 
that only leukocytes were counted and not erythrocytes, resulting in a far 
lower total cell count, the number of captured cells observed is reasonably 
close to the number of cells expected based on the approximate 
concentration of CTCs in the blood of cancer patients. 
Later stage metastatic patients may occasionally show far greater numbers of 
CTCs, such as the case with patient sample 29, and overall showed a greater 
range in the number of total captured cells compared with non-metastatic 
patients (Fig.6.14.). This variation in the number of CTCs captured in 
metastatic patients has been confirmed in other studies, for example, a study 
by Ulmer et al. (2004) captured between 1 and 456 CTCs in stage Ill patients 
(median=2) and between 1 and 2410 CTCs in stage IV patients (median=5)'. 
This variation in the number of CTCs seen in metastatic patients has also 
been observed in other malignancies. For example, Stott et al. (201 0) 
quantified CTCs in metastatic prostate cancer patients using an antibody 
coated chip which binds CTCs during mixing of patient blood. The results of 
this study showed that the number of CTCs in metastatic prostate cancer 
patients ranged from 12 to 3167 per ml of blood. The variation in the number 
of CTCs demonstrated in this study and by Stott et al. and Ulmer et al. may 
reflect variations in patient immune responses, disease history or individual 
responses to treatment. 
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7.5. The Influence of Patient Melanoma Recurrence on the Number of 
Captured Cells 
Table 6.7. shows all available information regarding the history of melanoma, 
including date of diagnosis of the most recent primary tumour and clinical 
history, for all 33 patients included in this study. This information may go 
someway to explaining the number of captured cells in some patients, 
although trends are difficult to determine as a result of huge variation in time 
since diagnosis and disease history within the small sample population. 
Despite the absence of trends, there are some interesting results, where the 
total number of captured cells seems to be at least somewhat explained by 
the patient's history of the disease. Patient 4 was diagnosed with in situ 
melanoma in 1996 and since excision of the tumour, there has been no 
disease recurrence reported. The total number of cells captured in this patient 
was 1, which is less than the mean number of cells captured from control 
samples (mean=3.71 ), suggesting that this patient has no CTCs, which is 
expected since the patient has been disease free for over 14 years. Patient 29 
has stage IV disease and had the largest number of total captured cells of any 
patient included in this study (232). This patient has had stage IV disease 
since 2003 and had nine separate secondary tumours removed in the five 
years following stage IV diagnosis. This large number of metastases along 
with the length of time this patient has had late stage disease may explain the 
large number of cells captured from this patient. 
Although it appears that some extreme high and low numbers of cells can be 
explained by clinical. history of the disease in some patients, there are other 
radical values which cannot be explained from the available information. For 
example, patient 6, a stage 0 patient with no disease recurrence had a large 
number of captured cells (64). Instances such as this make it difficult to 
determine any apparent relationships between the number of captured cells 
and clinical history of the disease. However, the large number of CTCs in this 
patient may indicate a risk of disease recurrence since primary tumour 
removal occurred in 2008 (Table 6.7.). 
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7.6. The Influence of Treatment on the Number of Captured Cells 
From the data available for patients included in this study, it is difficult to say 
whether treatment type has an influence on the number of circulating cells 
since only five patients were undergoing treatment at the time blood samples 
were taken (Table 6.7). Because of this and the fact that each of these five 
individuals is undergoing a different type, or combination of treatments, it is 
impossible to determine any trends in the results. Instead it can only be 
speculated as to whether the treatment any of these patients is undergoing 
has had an effect on the number of cells captured by immunomagnetic 
isolation. 
Patient 28, with stage IV disease, is currently undergoing a combination of 
radiotherapy and immunotherapy to combat their serious disease which has 
resulted in multiple metastases in various locations. The total number of cells 
captured from this patient's blood sample was 11, which is relatively low. It is 
possible that this combination of treatments is having some effect lessening 
the number of CTCs in this patient although due to limited information, this is 
difficult to determine. It was also noted that this patient sample had a relatively 
large amount of clumping, which resulted in a count lower than the actual 
number of cells present, as many cells could not be distinguished within these 
clumps. 
Patient 29, also with stage IV disease, has received a melanoma vaccine, as 
other more standard cancer therapies have been unsuccessful at treating 
their serious disease. This patient had by far the highest total number of 
captured cells which_may indicate that their treatment is ineffective at reducing 
the number of CTCs, and may therefore be ineffective at reducing the risk of 
metastasis formation. In contrast, patient 33, who recently had multiple 
metastases removed, had a relatively low number of total captured cells 
following adjuvant therapy, indicating that their treatment may have been 
successful at reducing CTC numbers. These examples suggest that the 
number of CTCs captured from patient blood samples may be indicative of 
patient treatment success, although it is difficult to determine due to the small 
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number of patients who were undergoing treatment, or had recently 
undergone treatment other than surgery, at the time of blood collection. 
7.7. Limitations of the Study 
7. 7. 1. Non-Specific Binding 
A few problems arose with the final protocol used for isolating CTCs which 
impacted on the results of this study. Firstly there was an issue with non-
specific binding of the beads resulting in cells being isolated from control 
blood samples. The initial high level of non-specific binding observed was 
reduced with the addition of 0.2% Triton X-1 00 to the washing buffer; however 
a low level of background binding remained. It is unclear whether this non-
specific binding was due to the antibody conjugated to the beads binding non-
specifically, control blood cells aberrantly expressing target markers, as a 
result of being ex vivo, or Fe receptors on the surface of immune cells binding 
antibody. There are a several products available that could be tested in future 
experiments in order to ensure these problems are not occurring. Firstly there 
are blood collection tubes designed to inhibit abnormal gene expression in 
blood cells, thus reducing the chance of them binding to antibody as a result 
of atypical marker expression. For example, Cyto-Chex Blood Collection 
Tubes (Streck, Omaha, USA) contain a cell preservative which maintains the 
integrity of blood cell marker expression for up to 7 days which would inhibit 
aberrant expression of melanoma markers in these cells. There are also a 
number of Fe receptor blockers available, which inhibit antibodies binding to 
Fe receptors on the surface of cells such as B cells, monocytes, and 
macrophages in order to reduce non-specific binding of antibodies to these 
cells. Melanoma cells, like the majority of tumour cells, are also Fe receptor 
expressing cells and therefore Fe receptor blocking would ensure 
immunomagnetic beads are binding to melanoma cells as a result of the 
coupled antibody binding to its target marker rather than to Fe receptors on 
the cell surface. 
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7. 7.2. Cell Clumping 
There was also an issue with clumping in samples, which resulted in clumps 
of cells forming during overnight incubation, which were removed by washing 
of the beads, or smaller clumps of cells forming, which survived washing and 
were seen during microscopy. Formation of cell clumps during incubation may 
have resulted in CTCs being lost during washing if they became a part of the 
clumps, whereas the presence of smaller clumps were a problem during cell 
counting by microscopy. These clumps often appeared as smears in which 
very few or no cells could be identified. This often resulted in a cell count less 
than the actual number of cells in the sample as only cells identified without 
doubt were counted. It is unsure whether these were clumps of melanoma 
cells, clumps of blood cells or a mixture of both. They could have been 
isolated from the rest of the sample as a result of magnetic beads becoming 
entangled in a cell clump or unbound cells clumping with bead bound cells 
resulting in clumps becoming bound by magnetic separation. Clumping was 
not observed in all blood samples and it did not appear to be related to either 
total cell count or the age of the sample. This suggests that some samples 
had a tendency to clump more than others possibly due to the cell 
composition of the sample. 
7. 7.3. Captured Cell Numbers in Early Disease Stages 
Results of this study demonstrate that CTCs are indeed present at early 
clinical disease stages, which may account for the significant number of 
patients with early stage disease who suffer recurrence. In some cases 
however, the number of cells captured in early stage, non-metastatic patients 
was much larger than expected. This could have been due to increased non-
specific binding in some patient samples, however, if it can be assumed that 
the amount of background non-specific binding is reasonably constant, and is 
similar to the amount of non-specific binding observed in other studies (Stott 
et al., 201 0), there may be another explanation for this. It doesn't appear that 
a large number of captured cells in early stage patients, for example patients 
6, 8 and 10, was related to the total cell count of the patient sample, which 
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suggests it may be the cell composition of the sample that has resulted in an 
increased number of bound cells. As discussed, there may be an issue with 
bead bound antibodies binding to Fe receptors on the surface of leukocytes. It 
could be the case therefore that if a patient has a heightened immune 
response to their tumour, which results in an increase in Fe receptor 
expressing cells, there may be an increase in non-specific binding. Of course 
it would also be case that metastatic patients would have a heightened 
immune response to their disease, although a large number of captured cells 
observed in early stage patients seems unusual and is less likely to be a large 
number of CTCs. Alternately, it may be the case that large numbers of cells 
enter circulation even at early disease stages although the immune system 
perhaps destroys the majority of these cells. Early stage patients with a large 
number of CTCs may therefore have a weakened immune response and large 
CTC numbers may indicate the possibility of disease relapse. This idea is 
supported by the fact that early stage patients with a relatively high number of 
captured cells generally had more primary tumours removed (Table 6.7.), 
indicating a large number of cells may correlate with a risk for disease 
recurrence. To confirm this, patients would need to be followed for several 
years to show an association between CTC numbers and disease recurrence. 
7.8. Suggested Future Experiments 
7.8.1. Staining Captured Cells 
Cells captured by immunomagnetic isolation should be stained with 
melanoma markers In order to confirm that they are in fact melanoma cells 
and not non-specifiqally bound leukocytes. Staining with the same antibodies 
used to isolate the cells from patient blood will show whether the cells are 
positive for these markers in order to confirm that the beads are binding cells 
specifically, via their conjugated antibody. Furthermore, staining these cells 
with other melanoma specific markers would demonstrate that they are 
melanoma cells rather than other cells that may be aberrantly expressing the 
markers that have been targeted in their isolation. Due to the fact that in this 
study there was a low level of non-specific binding, which has also been 
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observed in other studies (Stott et al., 201 0), staining captured cells is 
necessary to reveal the proportion of cells specifically bound verses non-
specifically bound in order to demonstrate the specificity of the assay. Stott et 
al. (201 0) in fact used immunostaining to produce a true CTC count in 
metastatic prostate cancer patients by staining with PSA (Prostate Specific 
Antigen) to confirm CTCs and CD45 (a leukocyte marker) to subtract non-
specifically bound leukocytes from CTC counts. 
Here we tested immunohistochemical and immunofluorescence staining using 
a number of different protocols and antibodies although results were largely 
unsuccessful. A major issue with staining captured cells was that the 
magnetic beads themselves strongly fluoresced under all wavelengths of the 
fluorescence microscope. This made it difficult for weak staining to be 
observed under any wavelength as sufficient exposure resulted in the 
fluorescence of the beads overpowering that of the cells. When staining was 
weak, this problem was exacerbated by fixing the cells with paraformaldehyde 
as it resulted in increased fluorescence of the beads. 
Incubating A2058 cells with anti-MCAM beads, fixing them with 2% 
paraformaldehyde and staining with anti-MCSP and anti-mouse lgG 
conjugated to Alexa Fluor 546 produced the most successful staining. In this 
protocol, cells were washed only after antibody incubation steps. The issue 
with fixing the cells before washing was that all non-specifically bound cells 
became fixed to the beads and could not be removed by washing. This was 
discovered when carrying out this method with HEK293 control cells which 
remained bound to the beads following washing, although they were 
unstained. 
In an attempt to overcome this problem, captured cells were washed 5 times 
with 0.2% Triton-X 100 in MAGS buffer, as per usual, before fixing with 2% 
paraformaldehyde and subsequently following the staining protocol. When this 
method was tested the cells did not stain, possibly because Triton X-100 had 
removed the cell surface proteins during washing. This explanation is 
supported by the fact that incubating cells with immunomagnetic beads 
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overnight in MAGS buffer containing 0.2% Triton X-100, instead of straight 
MAGS buffer, resulted in no cells binding to the beads. In order to overcome 
this problem, new washing buffers should be tested. It was also found 
following this protocol, upon viewing by microscopy, that many cells had 
become unbound from the beads and consequently were lost from the 
sample. This was possibly due to over-washing the sample, as a result of 
performing the standard washing protocol and subsequently washing the cells 
following fixing and again after each antibody incubation step. Simply 
reducing the total number of wash steps in the protocol may solve this 
problem otherwise a different washing buffer may be required. 
Due to the fact that strong staining was only seen following fixing the cells, 
which also fixed non-specifically bound cells, this method was not suitable for 
staining cells isolated from patient samples. This is because a true 
representation of the amount of specifically bound cells verses non-
specifically bound cells would not be shown. 
Staining the cells within the patient's total blood, following RBG lysis, before 
incubation with the beads was also tried. However it was found that washing 
and re-pelleting the cells in between antibody incubation steps resulted in loss 
of the cell pellet likely due to cell lysis. Problems with these methods need to 
be overcome in subsequent experiments in order to develop a sufficient 
protocol for staining isolated melanoma cells to sufficiently demonstrate that 
the circulating cell isolation protocol is specific and correctly captures 
circulating melanoma cells from blood. 
7.8.2. RT-PCR of C~ptured Cell RNA 
Similarly to staining captured cells, RT-PGR could also be used to detect the 
expression of melanoma markers in cells isolated by immunomagnetic beads. 
Using primers for the markers used to isolate circulating cells (MGSP, MGAM 
and ABGB5) would confirm that captured cells had bound specifically to the 
beads as a result of expression of these markers, while amplification of other 
melanoma specific markers will confirm that isolated cells are melanoma cells. 
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This technique has been performed in other studies which have isolated 
melanoma CTCs from patient blood by immunomagnetic beads in order to 
confirm that captured cells are in fact melanoma cells and to test for 
expression of specific markers in these cells (Kitago et al., 2009). 
The Dynabeads mRNA Direct kit (Invitrogen) was used to isolate mRNA from 
cells captured by immunomagnetic isolation for use in RT -PCR. This kit allows 
mRNA to be isolated from cells and tissue of various types with the use of 
magnetic beads covalently coupled to oligo (dT)2s which binds to the polyA tail 
of mRNA molecules following cell lysis. This mRNA can subsequently be used 
to manufacture eDNA which can be used in a PCR reaction to amplify 
melanoma specific markers. Once mRNA had been isolated from captured 
cells using the kit and had been converted to eDNA in a reverse transcriptase 
reaction, a real-time PCR reaction was performed with primers for GAPDH, a 
housekeeping gene constitutively expressed in all cell types. The reason for 
this was to show whether enough RNA had been isolated from the cells to 
allow PCR to be performed. The result of this real time reaction showed a 
small peak on the graph indicating GAPDH was present, although it took more 
than 40 cycles to appear which indicated that the amount of RNA isolated 
from the cells was extremely low; too low to provide any tangible results. This 
result was unsuccessful possibly due to the small amount of RNA contained in 
the samples, which consisted of very few cells. However it is feasible that this 
method would perform better following protocol optimisation to successfully 
isolate RNA from small cell numbers. There are other methods of RNA 
isolation suitable for small quantities of RNA that may also be useful for this 
application and should therefore be tested, for example RNA isolation with 
TRizol reagent (Invitrogen). 
7.9. Other Methods of Isolating Circulating Cells 
Recent studies have explored the use of methods other than 
immunomagnetic bead capture for the isolation of CTCs. Isolating CTCs from 
patient blood in order to characterise or quantify them is a relatively new area 
of research and as such, there are a number of studies being undertaken to 
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develop an optimal method of isolating these cells specifically and efficiently. 
As previously discussed, a study by Stott et al. (2010) has implemented an 
antibody coated chip that passively mixes patient blood allowing CTCs to 
come into contact with antibody bound to the chip which binds these cells and 
isolates them from whole blood. This study was able to capture CTCs in 93% 
of metastatic prostate cancer patients. Subsequent immunofluorescent 
staining confirmed bound cells were CTCs and eliminated false positives by 
staining with CD45, a leukocyte marker. 
A study by Kojima et al. (2009) used Green Fluorescent Protein (GFP) 
expressing attenuated adenovirus specific for telomerase to infect viable 
CTCs which could be detected as a result of GFP expression in infected cells 
following viral replication. CTCs were detected by automated scanning for 
GFP by fluorescence microscopy. Telomerase is expressed in many cancer 
cell types and results in maintenance of telomere lengths allowing these cells 
to divide without limit rendering them immortal. This study infected blood 
samples from patients with a variety of telomerase expressing malignancies 
with the GFP expressing virus and it was found that GFP expression could be 
detected in all viable CTCs 48 hours after infection. 
A study by De Giorgi et al. (2010) isolated CTCs from melanoma patients· by 
filtration as melanoma CTCs are larger than other blood cells (>161-Jm). 
Captured cells were confirmed as melanoma cells by performing RT-PCR to 
detect tyrosinase expression. Results of this study showed that CTCs were 
only captured in 62.5% of metastatic melanoma patients suggesting this 
technique may be less sensitive than immunomagnetic bead capture and 
other methods of <;;apturing CTCs. However, no CTCs were captured in 
controls or stage 0 patients suggesting it may be more specific than other 
methods of CTC isolation. 
Another study employed density gradient centrifugation, a technique used to 
separate cell types or cell components based on differences in density, in 
order to separate CTCs from whole blood in oesophageal carcinoma patients 
(Hoffmann et al., 201 0). RT-PCR was then performed to check captured cells 
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for survivin (SW) expression, a marker that varies in expression in response 
to treatment in gastrointestinal malignancies, in order to confirm they were 
CTCs. SW was detected in 77% of patients showing that this technique was 
reasonably successful. These novel techniques, along with immunomagnetic 
bead capture, show potential for optimal CTC isolation and therefore need to 
be explored further and tested in melanoma patients in order to determine 
which method is the most sensitive and specific for isolating circulating 
melanoma cells from patient peripheral blood. 
7.1 0. Characterising CTCs 
As well as allowing CTCs to be quantified, the use of immunomagnetic beads 
to isolate CTCs from patient blood would also allow characterisation studies to 
be performed in order to analyse the phenotype of these cells. The main idea 
of characterising these cells is to demonstrate differences in phenotype 
between early stage and late stage cells and to characterise an aggressive 
phenotype with high metastatic potential compared with a non-aggressive 
phenotype with low metastatic potential. Determining a series of markers 
associated with metastasis and aggressive behaviour would allow CTCs 
isolated from patient blood to be tested for these markers by RT-PCR in order 
to determine the patient's risk of metastasis and disease progression and thus 
improve prognosis. Characterising a patient's disease based on CTC marker 
expression would also allow specific treatment strategies to be implemented 
with the aim of targeting particular cell types in order to more effectively 
combat the disease. 
7.11. Conclusion 
In this study, it has been shown for the first time that the phenotype of 
melanoma CTCs can be differentiated since a metastatic circulating cell 
phenotype was identified which correlated with disease stage. A statistically 
significant relationship was demonstrated between the number of cells 
isolated with anti-MCAM coupled beads and disease stage. MCAM 
expression is associated with an aggressive and invasive phenotype with the 
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potential for metastasis and therefore quantification of MCAM positive CTCs 
may be useful in monitoring disease progression and assessing the 
requirement for treatment in early stage patients before the development of 
metastatic disease. This would be a significant clinical tool since currently 
there is no method of identifying early stage patients requiring treatment 
following surgical removal of their primary tumour, as although they are 
clinically residual disease free, many of these patients go on to develop 
metastatic disease (Jack et al., 2006; Koyanagi et al., 2005a; Weight et al., 
2006). 
Results of this study also indicate that there is no significant association 
between the total number of captured cells and disease stage. While future 
studies with larger patient populations may change this finding, it may indeed 
be the case that variation in melanoma CTCs is in the cell phenotype rather 
than the number of cells and this too is a significant finding. 
There were a number of issues that arose with the development of this cell 
capture protocol, such as non-specific binding and cell clumping, which need 
to be overcome in future experiments in order to increase the sensitivity and 
specificity of the assay. The use of immunofluorescent staining or RT-PCR to 
demonstrate marker expression in captured cells also needs to be explored 
further to verify that captured cells are in fact melanoma cells. Once these 
issues have been addressed and the protocol has been optimised, the 
effectiveness of immunomagnetic bead capture to isolate CTCs in melanoma 
patients should be compared with other recently developed techniques which 
have been utilised for the isolation of CTCs in other malignancies. 
Development of an _optimal strategy for the isolation of circulating melanoma 
cells will allow the relationship between CTCs and disease outcome to be 
further explored with the aim of improving prognosis and disease 
management. 
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Development of a Blood Test for Cutaneous Malignant Melanoma 
- Subject Information Sheet -
Purpose 
This study will investigate genes, proteins and cells that are abnormally present in the peripheral 
blood of patients with Cutaneous Malignant Melanoma or other forms of skin cancer but are not 
present in normal healthy individuals. It is anticipated that genes and proteins may be used as 
markers to identify cancer cells in the blood of patients as well as provide some indication of 
tumour progression. 
Background 
The genes and proteins that play a role in formation of normal skin cells are for the most part, well 
known. A different set of genes and proteins may be switched on or genes and proteins that are 
present in normal skin cells may be present in high levels in melanoma tumour cells but not in other 
skin cells. The reason for the expression of these genes and proteins in melanoma cells and their 
role in tumour development and progression is unknown. In order to provide more accurate 
diagnosis and treatments, it is important for medical scientists to understand the signals that lead to 
skin cancer formation and progression. Using genetic and protein markers, scientists are developing 
a blood test that can detect migrating melanoma cells in peripheral blood. Ultimately the test will be 
available for use as in routine diagnostic check ups. 
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Procedure 
Your participation requires you to donate a small sample of blood. The blood will be taken by a 
phlebotomist or your doctor who is working in collaboration with the researchers and may be 
providing clinically relevant details relating to the diagnosis of your disease. 
As a patient with Cutaneous Malignant Melanoma you will be asked to provide a small quantity 
(17 ml) of blood at the time of surgical removal of your tumour, or at routine follow up clinical 
visits six months, one year, two years and three years after surgery. 
If you are a patient with other forms of skin cancer or a volunteer providing your blood for controls, 
then you will only be required to provide your blood on a single occasion. 
You may be asked to provide consent for the use of your tissue which has been stored at pathology 
laboratories. The tissue required for this study will only be archival tissue no longer required for 
diagnostic or treatment purposes. You will not be asked to undergo any further procedures, merely 
to provide consent for the use of extraneous tissue. 
Risks 
In this study, the sample that you provide is a blood sample and there is very little risk to you in this 
procedure as only a small volume of blood is required for the test. You may also be asked to 
provide access to your archival tissue samples at no risk to yourself 
Benefits 
Individual: 
There are NO individual benefits from this study at this stage. However an examination of your skin 
for skin lesions is provided free of charge to you. As the research is at an early stage and no defmite 
conclusions can be drawn from the results of the blood test at this stage, results will be provided to 
your clinician upon request. However, should an abnormal result be obtained, you or your clinician 
will be informed and you will be assisted to make the necessary decisions about any changes to 
your treatment in accordance with the NHMRC guidelines for Human Research. 
Community: 
The results of this study may provide information about the role of genes, proteins and cells in 
tumour development and progression. The results may also help identify genes and proteins 
involved in tumour metastasis and therefore may at a future date, be used to assist with diagnosis 
and treatment of skin cancer, and malignant melanoma in particular. 
Confidentiality of Data 
Personal details will not be available to all researchers. Only the chief investigator will have your 
medical details and your name or patient number. Laboratory researchers will have your medical 
details only and your sample will be given a code number to protect your identity. Therefore you 
cannot be identified by laboratory researchers but collective results may be published. Your 
personal details may be obtained from medical records by your clinician only. 
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Subject Rights 
Participation in this research is voluntary and you are free to withdraw from the study at any time 
and for any reason, without prejudice in any way. 
The project has been approved by the Human Research Ethics Committee at Edith Cowan 
University (Project No. 2932) and by the Human Research Ethics Committee at Sir Charles 
Gairdner Hospital (Project No. 2007-123). These Human Research Ethics Committees are fully 
constituted ethics committees and follows guidelines laid down by the National Health and Medical 
Research Committee of Australia. 
If you have any questions or require any further information about the research project, please 
contact: 
Mel Ziman on telephone number 6304 5171 
If you have any concerns or complaints about the research project and wish to talk to an 
independent person, you may contact: 
Research Ethics Officer 
Edith Cowan University 
100 J oondalup Drive 
JOONDALUP WA 6027 
Phone: (08) 6304 2170 
Email: research.ethics@ecu.edu.au 
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Appendix 8 
PARTICIPANT INFORMATION SHEET 
Development of a blood test for Cutaneous Malignant Melanoma 
Research on the use of a blood test to monitor Melanoma progression 
A/Prof Mel Ziman, Dr Mark Brown, Prof. Michael Millward, Mr. Mark Lee, 
A/Prof Robert Pearce, Dr Prasad Kumarasinghe, Dr. Judith Cole, 
Mr James Freeman, Ms Tamara Esmaili. 
Please take time to read the following information carefully and discuss it with your 
friends, family and clinician if you wish. Ask us any question if some part of the 
information is not clear to you or if you would like more information. Please do this before 
you sign this consent form. 
Who is funding this study and where will it be conducted? 
I Edith Cowan University 
Contact persons: 
, Should you have questions about the study you may contact: 
A/Prof. Mel Ziman Phone No. 6304 5171 Mobile: 0419929851(after hours:) 
All study participants will be provided with a copy of the Information Sheet and Consent 
Form for their personal records. 
You may decide to be in the study or not take part at all. If you do decide to take part in 
this study, you may stop at any time. However, before you decide, it is important that 
you understand why this research is being done and what it will involve. 
Whatever your decision, this decision will not lead to any penalty or affect your regular 
medical care or any benefit to which you are otherwise entitled. 
The following information sheet will explain the study and will include details such 
as: 
o Why this trial might be suitable for you; 
o The possible risks (side-effects) and benefits of the new test; 
o The type, frequency and risks of any medical tests or procedures required by the 
trial; 
o The nature of your participation including how many visits you will make to the 
hospital 
o Your rights and responsibilities 
o Who is funding this study 
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What is the purpose of the study? 
This study is a research project in which we are investigating abnormalities in gene and 
protein expression in the peripheral blood of patients with Cutaneous Malignant 
Melanoma relative to gene expression in patients with other forms of skin cancer and to 
normal healthy individuals. It is anticipated that these genes and proteins may be used 
as markers to identify melanoma cells in the blood of patients as well as provide some 
indication of tumour progression. 
Over 900 participants will be involved. 
Why is this study suitable to me? 
You have been invited to participate in this study because you have been diagnosed with 
Cutaneous Malignant Melanoma, or you have been invited to participate because you 
have been diagnosed with another form of skin cancer or a mole or you are asked to 
participate as a normal healthy volunteer. 
How long will I be in this study? 
If you agree to participate you will be asked to undergo a skin examination by a 
practicing clinician (either a dermatologist or a plastic surgeon). This service will be 
provided free of charge if you are a healthy volunteer. 
You will then be asked to provide a blood sample. 
As a patient the blood sample will be taken before surgical removal of your tumour. If you 
are invited to participate as a patient with Cutaneous Malignant Melanoma you will be 
asked to provide additional blood samples at the time of routine clinical follow up visits to 
your clinician at 6 months, one year, two years and even three years after surgery. 
Clinical Visits Dates 
Before Surgical Removal of Tumour 
6 Month clinical follow up 
1 Year clinical follow up 
2 Year clinical follow up 
3 Year clinical follow up 
What will happen if I decide to be in this study? 
- The study will be conducted over a five year period. If you are a healthy volunteer yol) 
will be asked to undergo a free skin examination and provide one blood sample at a 
time that is suitable for you. 
- If you are a patient with a skin lesion you will be asked to provide one blood sample 
at the time of surgical removal of your lesion. 
- If you are a patient with Cutaneous Malignant Melanoma you will be required to give 
a blood sample five times over the course of three years. 
- The amount of blood required for this study is small (only 17 ml per visit). Blood will 
be drawn into two different types of blood tubes. 
- Generally you will not be contacted between visits. If you require general information 
about the research at any time then you are able to contact the researchers should 
you wish to do so. 
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- Your blood will be tested relative to blood from other participants and those of healthy 
volunteers. Because your sample is only identifiable by a coded number, the 
researchers performing the tests will not know which sample is yours. 
- samples will be stored in the locked freezers during the melanoma research study 
conducted at Edith Cowan University and will then be discarded upon completion of 
the study or upon your written request. 
Are there any reasons I should not be in this study? 
The clinical staff collaborating in this study will discuss these with you in detail and will 
ensure that this trial is both safe and appropriate for you. 
What are the costs to me? 
There will be no additional costs over and above your visits to the doctor. Blood will be 
taken at the hospital when and where you visit your doctor for treatment and follow up 
visits. 
What are the possible benefits of taking part? 
The results of these studies may be of interest to you and your family and you may 
decide whether or not the information may be disclosed to your family. 
However, the research will not at this stage provide you with any detailed information 
about your health or genetic diseases now or in the future. 
Donation of your sample may assist researchers to provide a more detailed and specific 
diagnosis of melanoma in the future. 
How will my safety be ensured? 
In this study, the sample that you provide is a blood sample and there is very little risk to 
you in this procedure as only a small volume of blood is required for the test. However 
please do not hesitate to contact the study coordinator or your doctor in relation to any 
adverse effects you think you are experiencing. If the effects are severe enough, the 
doctor may stop your participation in the study. You may also be asked to provide 
access to archival tissue samples that are stored in pathology laboratories where they 
were used for clinical diagnosis. Should this be the case only archival tissue samples wll 
be used and no fresh tissue is required and you will not be required to undergo any 
further surgical procedures. 
The clinician may find a lesion on your skin or the blood study may produce abnormal 
results in which case you and your clinician will be notified and additional clinical tests 
will be performed if your doctor feels it is in your best medical interest. 
What alternatives do I have to going on this study? 
Your participation is voluntary. This study does not affect your treatment or your health. 
Your treatment will continue in the same manner whether you decide to participate in the 
study or not. 
You may wish to discuss with your doctor or the researchers how the test will benefit 
patient treatment in the future even though there is no immediate benefit to your own 
treatment if you participate in the study. 
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What are the possible side effects, risks and discomforts of taking part? 
In this study, only a small volume of blood is taken (17 ml) at each scheduled visit so 
there is very little risk to you in this procedure. You may suffer a small amount of 
discomfort when you donate the blood sample, like the feeling of a pin prick. If archival 
tissue samples are used there is no additional risk to you. 
The likelihood of side effects from donating blood are small, around 1 in 100. 
However should you suffer any side effects please tell your doctor immediately about 
any new or unusual symptoms that you get. 
What if new information comes along during the study? 
Sometimes new information about a blood test becomes available as a study 
progresses. You will be told about any information that could be important to you and to 
your decision to continue in the study. If you then want to continue in the trial, you may 
be asked to sign a revised consent form. 
Stopping the study early: 
Sometimes a trial needs to be stopped early because of safety concerns, because the 
trial is not effective enough, or for other reasons. If this occurs, the reasons will be 
explained to you and your treatment will continue as it would have without the test. Your 
treatment will not be influenced by the test in any way. 
, What happens at the end of the study? 
At the end of the study your visits to your doctor will continue and your treatment will not 
be affected by the outcome of the research. 
What if something goes wrong? 
You will receive the best medical care available during and after the test, but because 
these are still relatively new tests, unexpected results may be obtained. In the unlikely 
event of risks to your health being identified then you will be provided with the necessary 
care. 
Medical treatment will be provided at no cost to you for research-related harm. The term 
"research-related harm" means both physical and mental injury caused by the product or 
procedures required by the trial. 
Your participation in this study does not prejudice any right to compensation which you 
may have under statute or common law 
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Will my taking part in this study be kept confidential? 
The researchers will need to collect personal data about you, which may be sensitive, 
such as your relevant health information. The researchers may also need to get some of 
your health information form other health service providers, eg another hospital, 
pathology laboratory, radiographer, GP or other medical specialist. 
Any personal or health information will be kept private and confidential. It will be stored 
securely and only authorised persons, who understand it must be kept confidential, will 
have access to it. Your study details will be given a number so that your identity will not 
be apparent. The trial records will be kept at The School of Exercise Biomedical and 
Health Science at Edith Cowan University during the study and in a locked archive for at 
least 5 years and for a maximum of 15 years from the time the study is closed, and may 
be destroyed at any time thereafter. 
Authorised representatives of the researchers, the investigating doctors, or University 
Human Research Ethics Committees, and other regulatory bodies may require access to 
your study records to verify study procedures and/or data. In all cases when dealing with 
your information, these people are required to comply with privacy laws that protect you. 
The result of the research will be made available to other doctors through medical 
journals or meetings, but you will not be identifiable in these communications. By taking 
part in this study you agree not to restrict the use of any data even if you withdraw. Your 
rights under any applicable data protection laws are not affected. 
Will I find out the results of the study? 
The value of the research is not known at this time. You will be notified of the results of 
the research in general terms at your request and the outcomes of the research as a 
whole may be provided to you upon completion of the project. 
Who has reviewed the study? 
The Edith Cowan University Human Research Ethics Committee and the Sir Charles 
Gairdner Hospital Human Research Ethics Committee have reviewed this study and 
have given approval for the conduct of this research trial. In doing so this study conforms 
to the principles set out by the National Statement on Ethical Conduct in Research 
involving Humans and according to the Good Clinical Practice Guidelines. 
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The Edith Cowan University and Sir Charles Gairdner Human Research Ethics 
Committees have given ethics approval for the conduct of this project. 
If you have any questions or require any further information about the research project, 
please contact: 
Mel Ziman on telephone number 6304 5171 
If you have any concerns or complaints about the research project and wish to talk to an 
independent person, you may contact: 
Research Ethics Officer 
Edith Cowan University 
100 Joondalup Drive 
JOONDALUP WA 6027 
Phone: (08) 6304 2170 
Email: research.ethics@ecu.edu.au 
Or the secretary of the Sir Charles Gairdner Hospital Human Research Ethics Committee 
on telephone No. (08) 9346.2999 
All study participants will be provided with a copy of the Information Sheet and 
Consent Form for their personal records. 
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CONSENT FORM 
Development of a Blood Test for Cutaneous Malignant Melanoma 
Investigators: A/Prof Mel Ziman, Dr Mark Brown, Prof. Michael Millward, , A/Prof. Robert 
Pearce, Mr. Mark Lee, Dr Prasad Kumarasinghe, Dr. Peter Heenan, Dr Judy Cole, Mr 
James Freeman, Ms Tammy Esmaili 
Participant Name: __________________ _ 
Date of Birth: ______ _ 
Address: _____________________ _ 
Phone Number: 
---------------------
Email:-----------------------
Name and address of GP 
------------------
, 1. I have been given clear information (verbal and written) about this study and have 
been given time to consider whether I want to take part. 
2. I have been told about the possible advantages and risks of taking part in the study 
and I understand what I am being asked to do. 
3. I have been able to have a member of my family or a friend with me while I was told 
about the study. I have been able to ask questions and all questions have been 
answered satisfactorily. 
4. I know that I do not have to take part in the study and that I can withdraw at any time 
during the study without affecting my future medical care. My participation in the 
study does not affect any right to compensation, which I may have under statute or 
common law. 
5. I provide consent for my medical history to be made available to the researchers. 
6. I agree to take part -in this research study and for the data obtained to be published 
provided my name or other identifying information is not used. 
If you are unclear about anything you have read in the Participant Information 
Sheet or this Consent Form, please speak to your doctor before signing this 
Consent Form. 
Name of Participant Signature of Participant 
Name of Investigator Signature of Investigator 
Date 
Date 
112 
Appendix C 
List of Abbreviations 
~1- Microlitre 
A488- Alexa-Fiuor 488 
ABCB5- ATP-Binding Cassette Subfamily B, Member 5 
AJCC- American Joint Committee on Cancer 
BSA- Bovine Serum Albumin 
CDKN2A- Cyclin-Dependent Kinase Inhibitor 2A 
CDK4- Cyclin-Dependent Kinase 4 
eDNA- Complementary Deoxyribonucleic Acid 
CMM- Cutaneous Malignant Melanoma 
CT- Computed Tomography 
CTC- Circulating Tumour Cell 
DAPI- 4' ,6-diamidino-2-phenylindole 
DMEM- Dulbecco's Modified Eagle Medium 
DNA- Deoxyribonucleic Acid 
EDTA- Ethylenediaminetetraacetic Acid 
EpCAM- Epithelial Cell Adhesion Molecule 
FBS- Foetal Bovine Serum 
Fe- Fragment Crystallizable 
FL 1- Fluorescence Channel1 
FL2- Fluorescence Channel 2 
GAPDH- Glyceraldehyde 3-phosphate dehydrogenase 
GFP- Green Fluorescent Protein 
HEK 293- Human Embryonic Kidney 293 
lgG- Immunoglobulin G 
LDH- Lactate Dehydrogenase 
MAGE-A3- Melanoma Antigen Gene A3 
MAPK- Mitogen-Activated Protein Kinase 
MART -1- Melanoma Antigen Recognised by T -Cells-1 
MC1 R- Melanocortin-1 Receptor 
MCAM- Melanoma Cell Adhesion Molecule 
MCSP- Melanoma Associated Chondroitin Sulphate Proteoglycan 
MITF- Microphthalmia-Associated Transcription Factor 
MRI- Magnetic Resonance Imaging 
mRNA- Messenger_ Ribonucleic Acid 
NGS- Normal Goat Serum 
PBS- Phosphate Buffered Saline 
PET- Positron Emission Tomography 
PSA- Prostate Specific Antigen 
qRT-PCR- Quantitative Reverse-Transcriptase Polymerase Chain 
Reaction 
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RBC- Red Blood Cell 
RGP- Radial Growth Phase 
RNA- Ribonucleic Acid 
RT -PCR- Reverse-Transcriptase Polymerase Chain Reaction 
SW- Survivin 
TYRP-1- Tyrosinase-Related Protein-1 
TYRP-2- Tyrosinase-Related Protein-2 
UV- Ultraviolet 
VGP- Vertical Growth Phase 
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